Bupivacaine
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | EXPAREL | — | 2018-04-06 – 2023-11-09 | fda.gov ↗ |
| Approved | EU (EMA) | Zynrelef | — | 2020-09-24 | europa.eu ↗ |
| Approved | US (FDA) | MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE | — | 1972-10-03 | fda.gov ↗ |
Trials 817 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 029 trials | ||||||
| Phase 0 | NCT07643506 | Jun 2026 → Jun 2027 expected | — | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07245290 | Nov 2025 → Jun 2026 overdue | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06349772 | Nov 2024 → Nov 2027 expected | — | Texas Tech University Health Sciences Center | Recruiting | No outcome recorded |
| Phase 0 | NCT06462573 | Sep 2024 → Sep 2026 expected | ureterolithiasis | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05461092 | Jan 2024 → Dec 2026 expected | delirium | University of Iowa | Recruiting | No outcome recorded |
| Phase 0 | NCT05925478 | Nov 2023 → Aug 2024 | acquired aneurysmal subarachnoid hemorrhage | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT05794828 | Sep 2023 → Feb 2025 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT06293807 | Jun 2022 → Apr 2023 | periodontal disorder | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT05122351 | Oct 2021 → Dec 2022 | — | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT05097118 | Sep 2021 → May 2022 | appendicitis | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT05069350 | Sep 2021 → Aug 2022 | — | Research Institute of Ophthalmology, Egypt | Completed | No outcome recorded |
| Phase 0 | NCT05022160 | Aug → Nov 2021 | prostate neoplasm, urinary bladder neoplasm | Armed Forces Hospital, Pakistan | Unknown | No outcome recorded |
| Phase 0 | NCT04335461 | Aug 2021 → Mar 2023 | — | Montefiore Medical Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT04985500 | Jul 2021 → Dec 2026 expected | — | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04611958 | Jul 2021 | chronic pancreatitis | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 0 | NCT04494880 | Dec 2020 → Dec 2022 | — | State University of New York - Upstate Medical University | Completed | No outcome recorded |
| Phase 0 | NCT04019834 | Jul 2020 → Nov 2021 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 0 | NCT04085913 | Sep 2019 → Jun 2024 overdue | parathyroid gland adenoma, thyroid gland disorder | University of Missouri-Columbia | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT03705637 | Jun 2019 → Mar 2020 | — | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 0 | NCT03867188 | Jan → Jun 2019 | soft tissue sarcoma | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 0 | NCT03731221 | Nov 2018 → Sep 2024 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 0 | NCT03243032 | Oct → Nov 2017 | neuropathy, painful | Satheesh Elangovan | Withdrawn | No outcome recorded |
| Phase 0 | NCT02991404 | Feb → Nov 2017 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 0 | NCT03070054 | Jun 2016 → Mar 2020 | — | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT02740192 | Apr → Dec 2016 | — | Henry Ford Health System | Completed | No outcome recorded |
| Phase 0 | NCT02485145 | Jul → Dec 2015 | osteoarthritis, hand | Transdermal Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 0 | NCT02285491 | Nov 2014 → Nov 2015 | — | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| Phase 0 | NCT00819962 | Sep 2014 → Dec 2015 | — | King Saud University | Unknown | No outcome recorded |
| Phase 0 | NCT00879164 | Apr 2009 → Dec 2010 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 131 trials | ||||||
| Phase 1 | NCT05575999 | Jan → Oct 2026 expected | — | Kansas City Heart Rhythm Research Foundation | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07429448 | Dec 2025 → Jun 2026 overdue | appendicitis | Sardar Umer Rehman | Recruiting | No outcome recorded |
| Phase 1 | NCT06500286 | Aug 2024 → Mar 2025 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06069791 | Jan 2024 → Dec 2026 expected | — | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06274008 | Oct 2023 → Oct 2024 | anxiety, opioid abuse | Children's Hospital of Orange County | Unknown | No outcome recorded |
| Phase 1 | NCT04908449 | Jun 2023 → Nov 2024 | coronary artery disorder, respiratory failure | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 1 | NCT05906433 | Jun 2023 → Jun 2025 overdue | osteoarthritis, knee | Foundation for Orthopaedic Research and Education | Recruiting | No outcome recorded |
| Phase 1 | NCT05664711 | Mar → Dec 2023 | myalgic encephalomeyelitis/chronic fatigue syndrome, post-infectious syndrome, post-viral disorder | Neuroversion, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06620614 | Oct → Dec 2022 | benign prostatic hyperplasia | National Academy of Medical Sciences, Nepal | Completed | No outcome recorded |
| Phase 1 | NCT05517486 | Jul → Aug 2022 | postherpetic neuralgia | Grace Therapeutics Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05588557 | Jul 2022 → Mar 2024 | neuropathy, painful | Nang Kuang Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05062356 | Nov 2021 → Aug 2024 | chronic pain syndrome | St. Mary's Research Center, Canada | Completed | No outcome recorded |
| Phase 1 | NCT05117021 | Nov 2021 → Apr 2022 | — | Sohag University | Unknown | No outcome recorded |
| Phase 1 | NCT04685421 | Jul 2021 → Jun 2023 | heart disorder | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT04331938 | Nov 2020 → Apr 2024 | acquired aneurysmal subarachnoid hemorrhage, headache disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT03177252 | Oct 2020 → Sep 2021 | brain neoplasm | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT04221568 | Mar 2020 → Mar 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT04189198 | Dec 2019 → Mar 2020 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT04293809 | Dec 2019 → Jan 2020 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04121338 | Dec 2019 → May 2021 | dysautonomia | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT04158102 | Nov → Dec 2019 | — | Nuance Pharma (shanghai) Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04002089 | Jul → Dec 2019 | toe, misshapen | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03729375 | Oct 2018 → Oct 2020 | carpal tunnel syndrome, neuropathy, painful | University of South Florida | Completed | No outcome recorded |
| Phase 1 | NCT03428984 | May → Sep 2018 | — | Pacira Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 1 | NCT03485014 | Apr 2018 → Feb 2019 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03399435 | Jan → Sep 2018 | — | Grünenthal GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT02985762 | Dec 2016 → Sep 2017 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03346993 | Jul 2016 | — | Erzurum Palandöken State Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02681796 | Jun 2016 → Feb 2020 | malignant pancreatic neoplasm | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00485667 | Jun → Aug 2007 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT00119184 | Oct 2002 → Mar 2006 | — | Hadassah Medical Organization | Terminated | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT04168710 | May 2025 → May 2027 | — | Yale University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06809998 | Jan 2025 → Aug 2026 overdue | osteoarthritis, knee | Unity Health Toronto | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03780478 | Jun 2019 → Dec 2021 | — | University of Southern California | Unknown | No outcome recorded |
| Phase 1/2 | NCT03040011 | Jun 2017 → Apr 2019 | pelvic organ prolapse | Lauren Giugale, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT02214810 | Jan → Sep 2015 | — | Broward Health | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01477190 | Oct 2010 → Oct 2011 | colon carcinoma, diverticulitis, inflammatory bowel disease | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 274 trials | ||||||
| Phase 2 | NCT07201987 | Jan 2027 → Jan 2028 expected | — | Ganesh M. Shankar | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07366905 | Feb → Mar 2026 | — | Hainan Medical College | Completed | No outcome recorded |
| Phase 2 | NCT06734975 | Jul 2025 → Dec 2026 expected | polyp of vocal cord | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT06635889 | Mar 2025 → Oct 2029 expected | nephrolithiasis | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT06270147 | Nov 2024 → Jan 2025 overdue | substance-related disorder | McMaster University | Recruiting | No outcome recorded |
| Phase 2 | NCT06655454 | Nov 2024 → Jun 2026 overdue | — | New York University | Recruiting | No outcome recorded |
| Phase 2 | NCT04744675 | May → Jul 2024 overdue | complex regional pain syndrome | Ottawa Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06429501 | Apr 2024 → Feb 2027 expected | — | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06002152 | Nov 2023 → Feb 2026 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT06411795 | Nov 2023 → Jan 2027 expected | pancreatic neoplasm, tumor of duodenum | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
| Phase 2 | NCT05734625 | Jul 2023 → Feb 2027 expected | migraine disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06766474 | Mar 2023 → Oct 2024 | — | Minia University | Completed | No outcome recorded |
| Phase 2 | NCT05736549 | Feb 2023 → Sep 2027 expected | osteoarthritis, knee | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT04427904 | Jun 2022 → Dec 2024 | thyroid gland disorder | St. Joseph's Healthcare Hamilton | Unknown | No outcome recorded |
| Phase 2 | NCT04911062 | Apr → Jul 2022 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05810012 | Apr → Oct 2022 | — | Pain Medicine Department | Completed | No outcome recorded |
| Phase 2 | NCT04477525 | Jun 2021 → Jun 2022 | neurological pain disorder | Montefiore Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT04717193 | May 2021 → Apr 2023 | appendicitis | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT04865211 | Apr 2021 → Feb 2022 | neuropathy, painful | The Cooper Health System | Unknown | No outcome recorded |
| Phase 2 | NCT05044468 | Mar 2021 → May 2026 overdue | pleural neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05355597 | Jan 2021 → Mar 2025 | musculoskeletal system disorder, soft tissue neoplasm | Atlantic Health System | Terminated | No outcome recorded |
| Phase 2 | NCT05324995 | Jan 2021 → Feb 2022 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04559347 | Dec 2020 → Jan 2024 | — | Poovendran Saththasivam | Terminated | No outcome recorded |
| Phase 2 | NCT04109885 | Sep 2020 → Jan 2024 | headache disorder | Christian Fromm, MD | Terminated | No outcome recorded |
| Phase 2 | NCT04207411 | Aug 2020 → Oct 2022 | — | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 2 | NCT04189783 | Jun 2020 → Oct 2024 overdue | retroperitoneal sarcoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04244097 | Apr → Jul 2020 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06893601 | Jan → Oct 2020 | — | Aydin Adnan Menderes University | Completed | No outcome recorded |
| Phase 2 | NCT03827213 | Jan 2019 → Jun 2021 | — | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03865147 | Jan → Jul 2019 | — | Medical Ethics UK Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT03958513 | Jan → Jul 2019 | — | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 2 | NCT03695367 | Oct → Nov 2018 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03545516 | Sep → Nov 2018 | substance-related disorder | Richmond University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03587636 | Sep 2018 → Mar 2021 | — | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT03433976 | May 2018 → May 2020 | — | University Hospital, Montpellier | Unknown | No outcome recorded |
| Phase 2 | NCT03393117 | Mar 2018 → Jul 2020 | breast cancer | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT03236324 | Sep 2017 → Oct 2022 | — | University of Calgary | Completed | No outcome recorded |
| Phase 2 | NCT03023982 | Feb 2017 → Feb 2019 | — | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03106519 | Jan → Jun 2017 | palmar fibromatosis | Catherine Vandepitte, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT03106545 | Jan → Jun 2017 | — | Catherine Vandepitte, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT02913573 | Sep 2016 → Sep 2018 | breast neoplasm | Huntington Memorial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02862691 | Aug 2016 → Aug 2017 | — | Stony Brook University | Terminated | No outcome recorded |
| Phase 2 | NCT02616367 | Dec 2015 → Dec 2016 | osteoarthritis, knee | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT03266081 | Apr 2015 → Aug 2022 | excessive tearing, ptosis | McMaster University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02343263 | Mar 2015 → May 2017 | neuropathy, painful | Indiana University | Terminated | No outcome recorded |
| Phase 2 | NCT02349581 | Nov 2014 → May 2015 | — | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 2 | NCT02188394 | Jul 2014 → Jan 2016 | migraine disorder | César Fernández-de-las-Peñas | Completed | No outcome recorded |
| Phase 2 | NCT02044302 | Apr 2014 → Jan 2016 | — | Yale University | Terminated | No outcome recorded |
| Phase 2 | NCT01969006 | Jan 2014 → Jan 2015 | — | Randers Regional Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01785459 | Oct 2013 → Jul 2016 | — | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT01826851 | Mar 2013 → Jun 2017 | coronary artery disorder | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT01878864 | Nov 2012 → Jun 2013 | periodontitis | Ove Andersen | Terminated | No outcome recorded |
| Phase 2 | NCT01667315 | Aug 2012 → Jan 2013 | — | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2 | NCT02007096 | Aug 2012 → Oct 2014 | abdominal wall malformation | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT01444924 | Sep 2011 → Feb 2013 | female reproductive organ cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT01224145 | Mar → Jun 2011 | — | Innocoll | Completed | No outcome recorded |
| Phase 2 | NCT01220024 | Dec 2010 → May 2011 | — | Innocoll | Completed | No outcome recorded |
| Phase 2 | NCT01559740 | Jul → Aug 2010 | — | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT01096966 | Mar 2010 → Feb 2011 | chronic pain syndrome | Durect | Completed | No outcome recorded |
| Phase 2 | NCT01133119 | Feb 2010 → Feb 2013 | — | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 2 | NCT01244932 | Sep 2009 → Jun 2011 | — | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT00993226 | May → Dec 2009 | — | Durect | Completed | No outcome recorded |
| Phase 2 | NCT00930072 | Apr 2009 → Dec 2014 | intracranial vasospasm | University of Washington | Terminated | No outcome recorded |
| Phase 2 | NCT01454609 | Jan 2009 → Jul 2010 | — | Jawaharlal Institute of Postgraduate Medical Education & Research | Completed | No outcome recorded |
| Phase 2 | NCT00818363 | Dec 2008 → Oct 2009 | — | Durect | Completed | No outcome recorded |
| Phase 2 | NCT01701414 | Nov 2008 → Feb 2012 | — | Rhode Island Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00661466 | Jul 2008 → Jan 2009 | — | Innocoll | Terminated | No outcome recorded |
| Phase 2 | NCT01662401 | May 2008 → Jan 2010 | — | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00626886 | Mar 2008 → Jan 2009 | — | Innocoll | Completed | No outcome recorded |
| Phase 2 | NCT00624910 | Dec 2007 → Sep 2008 | — | Innocoll | Completed | No outcome recorded |
| Phase 2 | NCT00974350 | Jan → Oct 2007 | — | Durect | Completed | No outcome recorded |
| Phase 2 | NCT00478179 | Sep 2006 → Dec 2007 | postherpetic neuralgia | Durect | Completed | No outcome recorded |
| Phase 2 | NCT00280553 | Apr 2005 → Apr 2013 | — | Margherita CADDEDU | Unknown | No outcome recorded |
| Phase 2 | NCT00050362 | Dec 2002 → Oct 2004 | — | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 2/321 trials | ||||||
| Phase 2/3 | NCT07555821 | Apr → Oct 2026 expected | — | South Egypt Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06456255 | Nov 2024 → May 2025 overdue | hemorrhagic disease, paranasal sinus disorder | Amin Javer | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06621329 | Oct 2024 → Jul 2026 overdue | headache disorder, subarachnoid hemorrhage | University of California, Davis | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05357690 | Apr 2023 → Jun 2026 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT05283980 | Nov 2022 → Mar 2025 overdue | neuropathy, painful, opioid abuse | Beth Israel Deaconess Medical Center | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04655339 | Jan 2020 → Sep 2021 | substance-related disorder | Baylor Research Institute | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05672680 | Dec 2019 → Aug 2023 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2/3 | NCT03739021 | Nov 2019 → Mar 2020 overdue | chronic pain syndrome | University of South Florida | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03408483 | Apr 2018 → May 2019 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2/3 | NCT02495220 | Jul 2015 → Nov 2017 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02393664 | Mar 2015 → Oct 2016 | lung neoplasm | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02374320 | Nov 2014 → Mar 2016 | CREST syndrome, Raynaud disease, diffuse scleroderma | Jose Soberon, MD | Terminated | No outcome recorded |
| Phase 2/3 | NCT03749408 | Dec 2012 → Jun 2014 | pulpitis | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT01683071 | Sep 2012 → Dec 2013 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 2/3 | NCT01616108 | Apr 2012 → Sep 2019 | Graves disease, esotropia, exotropia, ptosis | Smith-Kettlewell Eye Research Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT02030717 | Feb 2012 → May 2015 | renal cell carcinoma | Umeå University | Completed | No outcome recorded |
| Phase 2/3 | NCT00932542 | Apr 2010 → Feb 2011 | hemorrhoid | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2/3 | NCT01040273 | Dec 2009 → Dec 2010 | osteoarthritis, hip | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT00298571 | Feb 2006 → Oct 2007 | neuropathy, painful | University of South Florida | Completed | No outcome recorded |
| Phase 2/3 | NCT00472446 | Jan 2006 → Dec 2008 | — | Cantonal Hospital of St. Gallen | Completed | No outcome recorded |
| Phase 2/3 | NCT02847013 | ? → Dec 2019 | — | Milton S. Hershey Medical Center | Withdrawn | No outcome recorded |
| Phase 390 trials | ||||||
| Phase 3 | NCT07672236 | Jul → Dec 2026 expected | head and neck cancer, mucositis | OncoZenge AB | Recruiting | No outcome recorded |
| Phase 3 | NCT07212114 | Nov 2025 → Aug 2029 expected | — | Emory University | Recruiting | No outcome recorded |
| Phase 3 | NCT07092566 | Nov 2025 → Oct 2027 expected | renal carcinoma | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT06740214 | Sep 2025 → Jun 2027 expected | — | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 3 | NCT07257874 | Jul → Dec 2025 | — | Islamabad Medical and Dental College | Completed | No outcome recorded |
| Phase 3 | NCT06937385 | May 2025 → May 2026 overdue | cranial neuralgia, migraine disorder | HCA Florida North Florida Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06989866 | Dec 2024 → Aug 2026 overdue | — | United States Naval Medical Center, Portsmouth | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06665438 | Dec 2024 → Apr 2025 overdue | — | Al-Azhar University | Recruiting | No outcome recorded |
| Phase 3 | NCT06695858 | Nov 2024 → Oct 2025 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT06405724 | May 2024 → Dec 2025 | — | Feng Gao | Unknown | No outcome recorded |
| Phase 3 | NCT06349668 | Apr 2024 → Oct 2027 expected | congenital anomaly of kidney and urinary tract, kidney benign neoplasm, kidney cancer, ureter benign neoplasm +3 | Hans Bahlmann | Recruiting | No outcome recorded |
| Phase 3 | NCT05387317 | Apr 2024 → Jan 2025 | COVID-19 | Murdoch Childrens Research Institute | Withdrawn | No outcome recorded |
| Phase 3 | NCT05427500 | Mar 2024 → Jan 2026 overdue | post-traumatic stress disorder | The Royal's Institute of Mental Health Research | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06313632 | Mar 2024 → Mar 2025 | pleural disorder | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 3 | NCT06301503 | Mar → May 2024 | — | Udayana University | Completed | No outcome recorded |
| Phase 3 | NCT06430112 | Nov 2023 → May 2024 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT06088082 | Oct 2023 → Apr 2024 | — | King Saud Medical City | Unknown | No outcome recorded |
| Phase 3 | NCT05751421 | Feb 2023 → Feb 2024 | neuropathy, painful | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT05702827 | Jan 2023 → Mar 2024 | female stress incontinence, vulvar disease | TriHealth Inc. | Completed | No outcome recorded |
| Phase 3 | NCT07469826 | Oct 2022 → Apr 2023 | — | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| Phase 3 | NCT03883763 | Apr 2022 → Apr 2023 | — | Cristália Produtos Químicos Farmacêuticos Ltda. | Unknown | No outcome recorded |
| Phase 3 | NCT05264805 | Mar → Sep 2022 | neuropathy, painful | Hamdard University | Unknown | No outcome recorded |
| Phase 3 | NCT05300685 | Feb 2022 → Jul 2026 overdue | urethral stricture | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 3 | NCT05191745 | Jan 2022 → Apr 2023 | — | Jewish General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05133687 | Nov 2021 → May 2022 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05171179 | Oct 2021 → May 2025 | — | Northwestern University | Completed | No outcome recorded |
| Phase 3 | NCT04826484 | Oct 2021 → Apr 2023 | cryptorchidism, hydrocele, hypospadias, urinary system disorder | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 3 | NCT05285800 | Sep 2021 → Mar 2022 | — | Hamdard University | Completed | No outcome recorded |
| Phase 3 | NCT04974385 | Aug 2021 → Apr 2022 | — | University of Virginia | Completed | No outcome recorded |
| Phase 3 | NCT04928352 | Jun 2021 → Aug 2026 overdue | cleft palate | Assiut University | Recruiting | No outcome recorded |
| Phase 3 | NCT04785625 | Apr → Oct 2021 | abdominal wall malformation, neuropathy, painful | Innocoll | Completed | No outcome recorded |
| Phase 3 | NCT04117074 | Apr 2021 → Mar 2025 | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 3 | NCT04785638 | Apr 2021 → Jan 2023 | — | Innocoll | Completed | No outcome recorded |
| Phase 3 | NCT04764916 | Feb 2021 → Feb 2022 | — | Carilion Clinic | Unknown | No outcome recorded |
| Phase 3 | NCT04504812 | Feb 2021 → Apr 2025 | osteoarthritis, knee | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT04468542 | Jan 2021 → Dec 2022 | — | University of South Florida | Unknown | No outcome recorded |
| Phase 3 | NCT04173312 | Jan 2021 → Jan 2023 | — | Ascension Health | Unknown | No outcome recorded |
| Phase 3 | NCT04518462 | Oct 2020 → Apr 2021 | tarsal coalition, toe, misshapen | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT04910165 | Jun 2020 → Sep 2021 | arthropathy, substance-related disorder | St. Luke's Hospital, Pennsylvania | Completed | No outcome recorded |
| Phase 3 | NCT04426500 | Nov 2019 → Feb 2021 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 3 | NCT03974932 | Jun 2019 → Dec 2020 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT04461028 | Feb 2019 → Jun 2022 | rotator cuff syndrome | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 3 | NCT03762343 | Jan 2019 → Dec 2020 | infratentorial neoplasm | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03639389 | Jan 2019 → Mar 2022 | — | Karolinska Institutet | Completed | No outcome recorded |
| Phase 3 | NCT03508830 | Dec 2018 → Jan 2021 | substance-related disorder | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT03482973 | Jun 2018 → Nov 2019 | coronary artery disorder | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03432650 | Jun 2018 → Dec 2020 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 3 | NCT03326180 | Mar 2018 → Feb 2021 | osteoarthritis, knee | University of Leeds | Completed | No outcome recorded |
| Phase 3 | NCT02933814 | Feb 2018 → Feb 2019 | — | Loma Linda University | Withdrawn | No outcome recorded |
| Phase 3 | NCT03351348 | Nov 2017 → Nov 2026 expected | breast cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 3 | NCT03303794 | Oct 2017 → Jun 2018 | — | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT03295721 | Oct 2017 → Jan 2018 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03214510 | Oct 2017 → Jul 2027 expected | hepatobiliary disorder | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03261193 | Sep 2017 → Jun 2018 | neuropathy, painful | Nicholas Schott | Terminated | No outcome recorded |
| Phase 3 | NCT03262688 | Jun 2017 → Jan 2024 | — | Innocoll | Unknown | No outcome recorded |
| Phase 3 | NCT03151434 | Feb 2017 → Jul 2018 | — | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT01994967 | Nov → Dec 2016 | vertebral column disorder | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02949674 | Sep → Oct 2016 | — | Mexican Social Security Institute | Completed | No outcome recorded |
| Phase 3 | NCT02740114 | Aug 2016 → Jul 2020 | female reproductive organ cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT03304444 | Aug 2016 → Oct 2017 | female reproductive organ cancer | Abington Memorial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02336529 | Jul 2016 → Jul 2017 | breast cancer, neuropathy, painful | Kenneth Geving Andersen | Unknown | No outcome recorded |
| Phase 3 | NCT05004506 | Apr 2016 → Dec 2022 | chronic pain syndrome | Loyola University | Unknown | No outcome recorded |
| Phase 3 | NCT02601027 | Nov 2015 → Sep 2019 | female breast carcinoma | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT02525133 | Sep 2015 → Apr 2016 | — | Innocoll | Completed | No outcome recorded |
| Phase 3 | NCT02517905 | Aug 2015 → Jan 2016 | dental pulp disorder | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02523599 | Aug 2015 → Apr 2016 | neuropathy, painful | Innocoll | Completed | No outcome recorded |
| Phase 3 | NCT02752971 | Feb 2015 → Feb 2016 | — | Hospital Central Dr. Luis Ortega | Completed | No outcome recorded |
| Phase 3 | NCT03720223 | Jan 2015 → Oct 2017 | urethral stricture | Urology of Virginia | Completed | No outcome recorded |
| Phase 3 | NCT02480621 | Dec 2014 → Jun 2016 | — | Jamaica Hospital Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02299167 | Jan → Sep 2014 | — | Imam Abdulrahman Bin Faisal University | Completed | No outcome recorded |
| Phase 3 | NCT02282774 | Dec 2013 → Jun 2014 | — | King Saud University | Completed | No outcome recorded |
| Phase 3 | NCT02065219 | Nov 2013 → Apr 2014 | chronic pain syndrome | University of Copenhagen | Completed | No outcome recorded |
| Phase 3 | NCT02065804 | Oct 2013 → Jul 2014 | chronic pain syndrome | University of Copenhagen | Completed | No outcome recorded |
| Phase 3 | NCT01986049 | Feb → Aug 2013 | — | New York Presbyterian Brooklyn Methodist Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT02662660 | Jan 2012 → Dec 2015 | — | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 3 | NCT01318590 | Nov 2011 → Jun 2019 | chronic pancreatitis | University of Montreal Hospital Centre (CHUM) | Terminated | No outcome recorded |
| Phase 3 | NCT01367418 | Sep 2010 → Mar 2012 | prostate cancer | Örebro University, Sweden | Completed | No outcome recorded |
| Phase 3 | NCT01314144 | Aug 2010 → Jul 2011 | breast cancer | Cork University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01079455 | May 2010 → Jul 2012 | osteoarthritis, hip | University Hospital Pellenberg | Unknown | No outcome recorded |
| Phase 3 | NCT01052012 | Dec 2009 → Sep 2011 | — | Durect | Completed | No outcome recorded |
| Phase 3 | NCT03713762 | Oct → Nov 2009 | — | Centro Medico Docente la Trinidad | Completed | No outcome recorded |
| Phase 3 | NCT00890682 | Apr → Nov 2009 | toe, misshapen | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT00332735 | May 2006 → Jan 2007 | — | Reinier de Graaf Groep | Completed | No outcome recorded |
| Phase 3 | NCT00405262 | May 2006 → Oct 2008 | — | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT00358280 | Apr → Sep 2006 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00287326 | Jan → Jun 2006 | — | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 3 | NCT00197353 | Mar → Sep 1999 | — | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 3 | NCT00197327 | Feb 1998 → Mar 2000 | — | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 3 | NCT01303107 | — | — | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01308047 | — | — | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 4312 trials | ||||||
| Phase 4 | NCT07216586 | Jan 2027 → Jan 2028 expected | osteoarthritis, knee | University of Miami | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07246642 | Sep 2026 → Sep 2027 expected | erectile dysfunction | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07684365 | Aug 2026 → Dec 2027 expected | — | Beth Israel Deaconess Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07684989 | Jul 2026 → Jun 2027 expected | — | Mayo Hospital Lahore | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07650760 | Jul → Dec 2026 expected | — | Wah Medical college , POF hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07606911 | Jul 2026 → Jul 2027 expected | — | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07228039 | Jul 2026 → Jan 2028 expected | — | Duke University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07681648 | Jun → Nov 2026 expected | — | Engy Emil | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07616180 | Jun → Sep 2026 expected | — | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07570940 | Jun 2026 → Jun 2030 expected | atrial fibrillation, coronary artery disorder | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Show all 312 trials opens the full record — a long page | ||||||
| Phase not applicable253 trials | ||||||
| — | NCT07661212 | Sep 2026 → Sep 2027 expected | — | Bakirkoy Dr. Dr. Sadi Konuk Research and Training Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07658521 | Jul → Dec 2026 expected | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| — | NCT07651722 | Jun → Sep 2026 expected | paralytic ileus | Tianjin First Central Hospital | Recruiting | No outcome recorded |
| — | NCT07577934 | May → Jul 2026 overdue | — | Tianjin First Central Hospital | Recruiting | No outcome recorded |
| — | NCT07579975 | Apr → May 2026 overdue | — | Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07509866 | Apr → Oct 2026 expected | — | Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| — | NCT07338916 | Apr → Nov 2026 expected | — | Hospital del Trabajador de Santiago | Recruiting | No outcome recorded |
| — | NCT07458282 | Mar 2026 → Mar 2027 expected | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07458256 | Mar 2026 → Mar 2027 expected | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07440576 | Mar 2026 → Feb 2027 expected | pelvic organ prolapse | Erkan Gol | Recruiting | No outcome recorded |
| Show all 253 trials opens the full record — a long page | ||||||
| Phase not stated1 trial | ||||||
| — | NCT03969875 | Aug 2018 → Apr 2022 | osteoarthritis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1,374 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 038 trials | ||||||
| Phase 0 | NCT07485127 Comparator | Feb → Aug 2026 overdue | — | Sohag University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT07108465 Comparator | Jul → Sep 2025 overdue | impacted teeth, multiple | Henrique Tedesco | Recruiting | No outcome recorded |
| Phase 0 | NCT06617949 Comparator | Jan 2025 → Dec 2027 expected | substance-related disorder | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 0 | NCT06680167 Comparator | Oct 2024 → Nov 2025 | — | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT05824338 Comparator | Aug 2024 → Jul 2025 overdue | — | Fraser Health | Recruiting | No outcome recorded |
| Phase 0 | NCT07514130 Comparator | Aug 2024 → Jul 2025 overdue | preeclampsia | Menoufia University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06229054 Background | Feb → Jul 2024 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT07651488 Comparator | Mar → Sep 2023 | — | Liaquat National Hospital & Medical College | Completed | No outcome recorded |
| Phase 0 | NCT05687981 Comparator | Jan → Dec 2023 | — | Tanta University | Unknown | No outcome recorded |
| Phase 0 | NCT05315271 Comparator | Jun 2022 → Jan 2023 | — | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT05351489 Background | May 2022 → Oct 2023 | — | Mansoura University | Completed | No outcome recorded |
| Phase 0 | NCT05216770 Comparator | Mar 2022 → Aug 2027 expected | spasmodic dystonia | Massachusetts Eye and Ear Infirmary | Recruiting | No outcome recorded |
| Phase 0 | NCT05177991 Comparator | Mar 2022 → Dec 2024 overdue | abdominal wall malformation | Leslie Son | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05344495 Comparator | Jan → Jul 2022 | neuropathy, painful | Minia University | Unknown | No outcome recorded |
| Phase 0 | NCT04126824 Background | Jan 2022 → Aug 2026 overdue | adenomyosis, uterine benign neoplasm | University of California, Los Angeles | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06807554 Comparator | Jan 2022 | — | Liaquat National Hospital & Medical College | Completed | No outcome recorded |
| Phase 0 | NCT05244252 Comparator | Oct 2021 → Mar 2022 | — | Sheikh Zayed Medical College | Unknown | No outcome recorded |
| Phase 0 | NCT05019638 Comparator | Mar 2021 → May 2028 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04157075 Comparator | Mar 2021 → Oct 2022 | substance-related disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 0 | NCT04728308 Comparator | Jan → Apr 2021 | — | Armed Forces Hospital, Pakistan | Unknown | No outcome recorded |
| Phase 0 | NCT04101682 Comparator | Sep 2020 → May 2022 | tibial collateral ligament bursitis | Northwell Health | Terminated | No outcome recorded |
| Phase 0 | NCT04377204 Comparator | Jun 2020 → Dec 2022 | — | Our Lady of the Lake Hospital | Completed | No outcome recorded |
| Phase 0 | NCT04718259 Background | Jan 2020 → Feb 2021 | — | Tanta University | Completed | No outcome recorded |
| Phase 0 | NCT04110210 Comparator | Sep 2019 → Jul 2020 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT03885804 Comparator | Mar → Jul 2019 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT03388814 Comparator | Nov 2018 → Jun 2020 | breast cancer, neuropathy, painful, substance-related disorder | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 0 | NCT06499181 Comparator | Feb 2018 → Jan 2020 | neuropathy, painful | United States Naval Medical Center, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT03268525 Comparator | Sep 2017 → Nov 2019 | neuropathy, painful | Wolfson Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT03059498 Comparator | Jun → Nov 2017 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 0 | NCT03411330 Comparator | Jan 2017 → Apr 2018 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT03264430 Comparator | Jan 2017 → Oct 2018 | anal fistula, hemorrhoid | Esam Eldin Mohamed Abdalla | Unknown | No outcome recorded |
| Phase 0 | NCT02825056 Comparator | Jul 2016 → Jun 2017 | vascular disorder | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 0 | NCT03746418 Comparator | Jan 2016 → Jan 2018 | spondylolisthesis | Tanta University | Completed | No outcome recorded |
| Phase 0 | NCT03734848 Comparator | Jan 2016 → Jan 2018 | — | Tanta University | Completed | No outcome recorded |
| Phase 0 | NCT02680548 Comparator | Nov 2015 → Dec 2017 | neuropathy, painful | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 0 | NCT02365909 Comparator | Jun 2015 → Aug 2016 | headache disorder | University of Arkansas | Terminated | No outcome recorded |
| Phase 0 | NCT02369523 Comparator | Sep 2014 → Apr 2017 | — | University of Utah | Terminated | No outcome recorded |
| Phase 0 | NCT02168959 Comparator | Feb 2013 → Dec 2014 | — | University of Utah | Completed | No outcome recorded |
| Phase 153 trials | ||||||
| Phase 1 | NCT07380139 Comparator | Feb → Dec 2026 expected | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT07332130 Comparator | Dec 2025 → Jan 2026 overdue | — | Minia University Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07182110 Comparator | Aug 2025 → Aug 2026 overdue | gallbladder disorder | Makassed General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07049835 Comparator | Jun 2025 → Jul 2026 overdue | — | Makassed General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07023991 Background | May → Aug 2025 overdue | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06935669 Comparator | Apr 2025 → Apr 2026 overdue | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06917898 Comparator | Apr 2025 → Apr 2026 overdue | — | Makassed General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05695339 Background | Mar → Oct 2025 | Morton neuroma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT06714279 Background | Mar 2025 → Jun 2026 overdue | gallbladder disorder | Royal College of Surgeons, Ireland | Recruiting | No outcome recorded |
| Phase 1 | NCT07149168 Comparator | Dec 2024 → Jun 2025 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT06668220 Comparator | Nov 2024 → Oct 2026 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06882369 Comparator | Nov 2024 → Jun 2025 overdue | — | Minia University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06639503 Background | Nov 2024 → Sep 2026 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 1 | NCT07140627 Background | Aug 2024 → Jan 2025 | — | Allama Iqbal Medical College | Completed | No outcome recorded |
| Phase 1 | NCT06271265 Comparator | Mar 2024 → Jan 2027 expected | — | Pacira Pharmaceuticals, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT06294665 Comparator | Mar → Dec 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 1 | NCT04260854 Comparator | Jan 2024 → May 2026 overdue | — | Northwestern University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06502262 Comparator | Jan → Aug 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT07051512 Background | Jul 2023 → Jun 2024 | — | Tanta University | Completed | No outcome recorded |
| Phase 1 | NCT05918796 Comparator | Jun → Aug 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT05456490 Comparator | Apr 2023 → Feb 2025 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05707754 Comparator | Mar 2023 → Aug 2024 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT06077214 Comparator | Jan 2023 → Aug 2024 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1 | NCT05638620 Background | Jan → Jun 2023 | COVID-19, dysautonomia, dysautonomia-like disorder, long COVID-19 +1 | Jonathann Kuo, MD | Completed | No outcome recorded |
| Phase 1 | NCT05537883 Comparator | Nov 2022 → Dec 2023 | morbid obesity | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT05245721 Comparator | Mar 2022 → Jan 2023 | — | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT04479371 Comparator | Jul 2021 → Jul 2022 | hypospadias | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT04445337 Background | Nov 2020 → Oct 2021 | COVID-19, acute respiratory distress syndrome | University of Nebraska | Terminated | No outcome recorded |
| Phase 1 | NCT04532775 Background | Aug → Dec 2020 | peripheral neuropathy | Fayoum University | Unknown | No outcome recorded |
| Phase 1 | NCT04173611 Comparator | Jun → Dec 2020 | — | Pacira Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 1 | NCT04169256 Comparator | Mar → Jul 2020 | — | Fruithy Medical Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04011098 Comparator | Jul 2019 → Nov 2020 | obstetric disorder | University of Saskatchewan | Terminated | No outcome recorded |
| Phase 1 | NCT03957499 Comparator | May → Dec 2019 | — | Samaa Rashwan | Unknown | No outcome recorded |
| Phase 1 | NCT03918187 Background | Apr → Aug 2019 | — | Zagazig University | Completed | No outcome recorded |
| Phase 1 | NCT04585867 Comparator | Oct 2017 → Oct 2023 | — | University of Kansas Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT03234374 Comparator | Jun → Aug 2017 | — | Innocoll | Completed | No outcome recorded |
| Phase 1 | NCT02973958 Background | Feb 2017 → Jun 2018 | balanitis, neuropathy, painful, paraphimosis | Alberta Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02982889 Comparator | Dec 2016 → Mar 2017 | — | Liquidia Technologies, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03074773 Comparator | Oct 2016 → Mar 2017 | aorta coarctation | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT03261921 Comparator | Jun 2016 → Jun 2017 | — | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT02400645 Comparator | Mar 2015 → May 2016 | — | University of Tennessee | Terminated | No outcome recorded |
| Phase 1 | NCT02398123 Comparator | Mar → Jun 2015 | — | Mansoura University | Completed | No outcome recorded |
| Phase 1 | NCT02775318 Background | Sep 2014 → Apr 2015 | intracranial vasospasm | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 1 | NCT02210247 Comparator | Aug → Sep 2014 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02515422 Comparator | Jun 2014 → May 2015 | — | Huseyin Aksoy | Completed | No outcome recorded |
| Phase 1 | NCT01920373 Comparator | Nov 2013 | osteoarthritis | Kaiser Permanente | Withdrawn | No outcome recorded |
| Phase 1 | NCT01786655 Background | May 2013 → Mar 2014 | — | Charles Berde | Completed | No outcome recorded |
| Phase 1 | NCT01688362 Comparator | Nov 2012 → May 2014 | rotator cuff syndrome | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 1 | NCT01688596 Comparator | Sep → Dec 2012 | — | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01468415 Background | Jun 2011 → Jun 2013 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT00779467 Background | Oct 2008 → Nov 2013 | — | Wake Forest University | Completed | No outcome recorded |
| Phase 1 | NCT00195312 Background | Aug 2005 → Aug 2007 | HIV infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00001088 Background | Jul 1997 → Feb 2001 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/222 trials | ||||||
| Phase 1/2 | NCT07482709 Comparator | Nov 2025 → Mar 2026 overdue | — | Liaquat National Hospital & Medical College | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06382220 Comparator | Apr → Jul 2024 | — | Fayoum University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT06362915 Comparator | Jan → Jul 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05590234 Comparator | Nov 2022 → Jul 2023 | — | October 6 University | Completed | No outcome recorded |
| Phase 1/2 | NCT05257941 Comparator | Jan 2022 → Aug 2024 | — | Indiana University | Terminated | No outcome recorded |
| Phase 1/2 | NCT05109416 Comparator | Oct 2021 → Mar 2022 | — | Minia University | Completed | No outcome recorded |
| Phase 1/2 | NCT04926454 Background | Sep 2020 → Oct 2021 | neuropathy, painful | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04398329 Comparator | May 2020 → Jul 2021 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT05369468 Comparator | Jan 2020 → Nov 2022 | — | Tanta University | Completed | No outcome recorded |
| Phase 1/2 | NCT03970655 Background | Sep 2019 → Jan 2026 overdue | chronic rhinosinusitis | University of Florida | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04033471 Comparator | Jul 2019 → Mar 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03453151 Background | May 2018 → Jun 2019 | heart failure | Duke University | Completed | No outcome recorded |
| Phase 1/2 | NCT03024957 Comparator | Jan 2017 → Sep 2018 | immunodeficiency disease | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03066544 Comparator | Nov 2016 → Dec 2019 | migraine disorder | Hartford HealthCare | Unknown | No outcome recorded |
| Phase 1/2 | NCT02654860 Background | Nov 2016 → Feb 2019 | — | Sintetica SA | Completed | No outcome recorded |
| Phase 1/2 | NCT02935933 Comparator | Oct 2016 → Sep 2017 | chronic pain syndrome | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03560362 Comparator | Jul 2015 → Oct 2018 | lung cancer, neuropathy, painful | University of Tennessee | Unknown | No outcome recorded |
| Phase 1/2 | NCT02462681 Comparator | May 2015 → Dec 2016 | chronic pain syndrome | Assiut University | Completed | No outcome recorded |
| Phase 1/2 | NCT02031510 Comparator | Jan 2014 → Feb 2015 | — | Imam Abdulrahman Bin Faisal University | Completed | No outcome recorded |
| Phase 1/2 | NCT02065947 Background | Oct 2013 → Mar 2014 | — | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01565512 Comparator | Nov 2011 → Jul 2014 | prostate cancer | Columbia University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00672347 Comparator | Jul → Sep 2008 | — | Federal University of Minas Gerais | Completed | No outcome recorded |
| Phase 2119 trials | ||||||
| Phase 2 | NCT07616882 Comparator | Apr → Sep 2027 expected | — | Liaquat National Hospital & Medical College | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07689162 Comparator | Jul 2026 → Jun 2027 expected | neuropathy, painful | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07465185 Comparator | Mar → Sep 2026 expected | — | Benha University | Recruiting | No outcome recorded |
| Phase 2 | NCT07574385 Comparator | Mar → Aug 2026 overdue | toe, misshapen | Rebel Medicine Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT06529432 Comparator | Mar → Nov 2026 expected | — | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Show all 119 trials opens the full record — a long page | ||||||
| Phase 2/354 trials | ||||||
| Phase 2/3 | NCT06956950 Comparator | May → Oct 2025 overdue | — | Tanta University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05161637 Comparator | Apr → Dec 2025 | — | Taiwan Liposome Company | Unknown | No outcome recorded |
| Phase 2/3 | NCT06662175 Background | Nov 2024 → Jul 2025 overdue | — | Lady Reading Hospital, Pakistan | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06559969 Comparator | Sep 2024 → Dec 2026 expected | — | University of Iowa | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06350981 Comparator | Apr 2024 → Jan 2026 overdue | substance-related disorder | Foundation for Orthopaedic Research and Education | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT07590752 Background | Mar 2024 → Jun 2026 overdue | neuropathy, painful, substance-related disorder | Sahiwal medical college sahiwal | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06728514 Background | Jan → Jul 2024 | hypertensive disorder | Sahiwal medical college sahiwal | Completed | No outcome recorded |
| Phase 2/3 | NCT06077422 Comparator | Jan 2024 → Jan 2027 expected | heart disorder | Rutgers, The State University of New Jersey | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT06148168 Comparator | Jan 2024 → Jan 2025 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT06180031 Comparator | Jan 2024 → Jan 2025 | bone disorder | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT06166108 Comparator | Dec 2023 → Nov 2024 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT06046105 Comparator | Sep 2023 → Mar 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05781854 Comparator | May 2023 → Mar 2025 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05727098 Comparator | Jan → Apr 2023 | breast cancer | National Cancer Institute, Egypt | Completed | No outcome recorded |
| Phase 2/3 | NCT05813158 Comparator | Sep → Dec 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT06531603 Background | Feb 2022 → Jan 2023 | hypotensive disorder | Sahiwal medical college sahiwal | Completed | No outcome recorded |
| Phase 2/3 | NCT04429893 Background | Jan → Sep 2022 | breast cancer, chronic pain syndrome | Alexandria University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05271253 Comparator | Apr → Nov 2021 | acute kidney injury | Alexandria University | Completed | No outcome recorded |
| Phase 2/3 | NCT06735443 Background | Mar 2021 → Apr 2022 | hernia, double inguinal | Sahiwal medical college sahiwal | Completed | No outcome recorded |
| Phase 2/3 | NCT04813016 Background | Mar 2021 → Apr 2022 | — | National Cancer Institute, Egypt | Completed | No outcome recorded |
| Phase 2/3 | NCT04480775 Background | Jul → Dec 2020 | — | ghada fouad | Completed | No outcome recorded |
| Phase 2/3 | NCT04118101 Comparator | Oct 2019 → Dec 2020 | — | Theodor Bilharz Research Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT03863977 Comparator | Mar → Dec 2019 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03730714 Comparator | Nov 2018 → Aug 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03592537 Comparator | Aug 2018 → Apr 2021 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03388671 Comparator | Dec 2017 → Dec 2020 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03328299 Comparator | Nov 2017 → Dec 2018 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03307590 Comparator | Oct → Dec 2017 | — | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT03652116 Comparator | Apr 2017 → Jun 2018 | obstetric disorder | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT03060070 Comparator | Mar → Jun 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02959996 Comparator | Mar → Sep 2017 | neuropathy, painful | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03248648 Comparator | Mar → Sep 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03036085 Comparator | Feb → Dec 2017 | local anesthetic poisoning, neuropathy, painful, opiate dependence | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03063671 Comparator | Jan → Jul 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03005171 Comparator | Jan → Jul 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02988700 Comparator | Nov 2016 → Oct 2018 | neuropathy, painful | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02976597 Comparator | Nov 2016 → Jun 2018 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03098420 Comparator | Jul 2016 → May 2021 | — | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 2/3 | NCT02930707 Comparator | Jan → Jun 2016 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02923869 Comparator | Jan → Oct 2016 | cleft palate | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02514980 Comparator | Aug 2015 → Aug 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02487355 Comparator | May 2015 → Dec 2017 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02462174 Comparator | May → Sep 2015 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02341079 Comparator | Mar → Oct 2015 | osteoarthritis, knee | United States Naval Medical Center, San Diego | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02455609 Comparator | Mar → Aug 2015 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02707250 Comparator | Mar 2015 → Feb 2016 | — | Iuliu Hatieganu University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 2/3 | NCT02752308 Comparator | Sep 2014 → Mar 2015 | hypospadias | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02385435 Comparator | Jan → Aug 2014 | — | University of Jordan | Completed | No outcome recorded |
| Phase 2/3 | NCT01957631 Comparator | Jun 2013 → Jun 2019 | plantar fasciitis | King Hamad University Hospital, Bahrain | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02435537 Comparator | May 2013 → Mar 2015 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT01394523 Comparator | Aug 2011 → Sep 2016 | — | Nationwide Children's Hospital | Terminated | No outcome recorded |
| Phase 2/3 | NCT01582607 Comparator | Jan 2010 → Apr 2012 | neonatal compartment syndrome | University of Patras | Unknown | No outcome recorded |
| Phase 2/3 | NCT01558713 Comparator | Jan 2010 → Sep 2012 | neonatal compartment syndrome | University of Patras | Unknown | No outcome recorded |
| Phase 2/3 | NCT00947765 Comparator | Jan 2007 → Jun 2008 | epicondylitis | Dojode, Chetan M., MBBS, MS | Completed | No outcome recorded |
| Phase 3104 trials | ||||||
| Phase 3 | NCT07663435 Comparator | Jul → Dec 2026 expected | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07665762 Comparator | Jun 2026 → Sep 2028 expected | — | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07573969 Comparator | May 2026 → May 2027 expected | — | Ain Shams University | Recruiting | No outcome recorded |
| Phase 3 | NCT07467356 Comparator | Mar → Aug 2026 overdue | — | Benha University | Recruiting | No outcome recorded |
| Phase 3 | NCT07326397 Background | Feb 2026 → Nov 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07370181 Comparator | Jan → Jul 2026 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07327879 Background | Jan → Nov 2026 expected | benign shuddering attacks | Al-Azhar University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07222748 Comparator | Nov 2025 → Jun 2026 overdue | — | TLC Biopharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07194694 Comparator | Oct 2025 → Jan 2026 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT07027540 Comparator | Aug 2025 → Aug 2026 overdue | gallbladder disorder | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07013955 Comparator | Apr → Nov 2025 overdue | — | Minia University | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06873906 Background | Mar 2025 → Mar 2026 overdue | heart septal defect | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06810375 Comparator | Mar 2025 → Feb 2028 expected | lung cancer | George Washington University | Recruiting | No outcome recorded |
| Phase 3 | NCT06789575 Comparator | Mar 2025 → Mar 2026 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06789393 Comparator | Mar 2025 → Mar 2026 overdue | hypospadias | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06721832 Comparator | Jan → May 2025 | — | Benha University | Completed | No outcome recorded |
| Phase 3 | NCT06593665 Background | Sep 2024 → Dec 2026 expected | testicular cancer | Indiana University | Recruiting | No outcome recorded |
| Phase 3 | NCT06319859 Comparator | Aug 2024 → Oct 2025 | neuropathy, painful | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT06386770 Comparator | Jun 2024 → Feb 2025 | — | Aswan University | Unknown | No outcome recorded |
| Phase 3 | NCT06235606 Comparator | May 2024 → Nov 2025 | — | The University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT06284434 Comparator | Apr 2024 → Apr 2026 overdue | cleft lip/palate | Kerry O'Rourke | Recruiting | No outcome recorded |
| Phase 3 | NCT06179004 Comparator | Apr 2024 → Oct 2026 expected | — | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Phase 3 | NCT06812741 Background | Feb → Jul 2024 | — | Pakistan Navy Station Shifa Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05964868 Comparator | Feb 2024 → Dec 2026 expected | — | Jessyka Lighthall | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05763667 Comparator | Jan → Jul 2024 | female reproductive organ cancer | Tufts Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT06871033 Background | Jan → Dec 2024 | — | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT06165679 Comparator | Dec 2023 → Jun 2025 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT06137924 Background | Dec 2023 → Apr 2024 | — | Universidad Simón Bolívar | Unknown | No outcome recorded |
| Phase 3 | NCT06616441 Comparator | Jun 2023 → Sep 2024 | — | El Shatby University Hospital for Obstetrics and Gynecology | Completed | No outcome recorded |
| Phase 3 | NCT05671081 Background | Jan 2023 → Mar 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05802979 Comparator | Jan → Sep 2023 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT05624151 Comparator | Nov 2022 → May 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05603832 Background | Nov 2022 → Nov 2023 | — | Arthritis Innovation Corporation | Completed | No outcome recorded |
| Phase 3 | NCT05491187 Comparator | Sep 2022 → Apr 2023 | — | Tribhuvan University Teaching Hospital, Institute Of Medicine. | Completed | No outcome recorded |
| Phase 3 | NCT05444751 Background | Mar 2022 → Sep 2026 expected | lumbar disk disease, radiculopathy | Hospital for Special Surgery, New York | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05099055 Comparator | Mar 2022 → Jan 2023 | — | St. Justine's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05233683 Background | Mar 2022 → Mar 2023 | childhood acute lymphoblastic leukemia | King Saud University | Unknown | No outcome recorded |
| Phase 3 | NCT05157841 Comparator | Feb → Aug 2022 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT05139030 Comparator | Jan → Jul 2022 | osteoarthritis, knee | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT05161221 Comparator | Dec 2021 → Dec 2022 | neuropathy, painful | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT04979338 Comparator | Nov 2021 → Sep 2026 expected | body integrity dysphoria | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT04825704 Comparator | Oct 2021 → Jun 2023 | — | Nordland Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04685876 Comparator | Jun 2021 → Feb 2024 | — | Edward Mascha | Completed | No outcome recorded |
| Phase 3 | NCT04613830 Comparator | Nov 2020 → Nov 2022 | childhood malignant neoplasm | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT04668456 Comparator | Aug 2020 → Mar 2021 | — | Menoufia University | Unknown | No outcome recorded |
| Phase 3 | NCT05084573 Comparator | Aug 2020 → Jul 2022 | — | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT03954639 Comparator | Jun → Sep 2020 | toe, misshapen | Pacira Pharmaceuticals, Inc | Withdrawn | No outcome recorded |
| Phase 3 | NCT03183596 Comparator | Dec 2019 → Aug 2020 | — | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 3 | NCT04300231 Comparator | Oct 2019 → Dec 2021 | — | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT04849858 Comparator | May 2019 → Jan 2023 | leiomyoma, ovarian cancer, uterine cancer | University of California, Irvine | Terminated | No outcome recorded |
| Phase 3 | NCT04003987 Comparator | May 2019 → Mar 2021 | — | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT03907176 Background | Apr 2019 → Oct 2021 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03682302 Comparator | Apr → Aug 2019 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT03859635 Comparator | Feb 2019 → Nov 2022 | — | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT03463915 Comparator | Jan 2019 → Oct 2020 | interstitial cystitis | Olivia Cardenas-Trowers, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT03270514 Comparator | Nov 2018 → Dec 2019 | coronary stenosis, mitral valve insufficiency, tricuspid valve insufficiency | Kathirvel Subramaniam | Completed | No outcome recorded |
| Phase 3 | NCT03702621 Comparator | Aug 2018 → Mar 2020 | colorectal cancer | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT03682224 Comparator | Jul 2018 → Sep 2022 | non-small cell lung carcinoma | Southern Illinois University | Completed | No outcome recorded |
| Phase 3 | NCT02973048 Comparator | Mar → Nov 2018 | hypotensive disorder | Centre Hospitalier Universitaire Saint Pierre | Completed | No outcome recorded |
| Phase 3 | NCT03434678 Background | Jan 2018 → Jul 2024 | malignant pancreatic neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT03359811 Comparator | Nov 2017 → Nov 2020 | peritoneum cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT03043027 Comparator | Aug 2017 | nephrolithiasis | Northwell Health | Withdrawn | No outcome recorded |
| Phase 3 | NCT03027661 Comparator | Aug 2017 → Jun 2018 | neuropathy, painful | University of Tennessee | Completed | No outcome recorded |
| Phase 3 | NCT03237481 Comparator | Jul → Dec 2017 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03063073 Comparator | Feb → May 2017 | female breast carcinoma | South Egypt Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT03009500 Comparator | Jan 2017 → Mar 2018 | neuralgia, neuropathy, painful | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT02891798 Background | Oct 2016 → Jul 2021 | — | Brian Williams | Completed | No outcome recorded |
| Phase 3 | NCT03110003 Comparator | Jun 2016 → Dec 2017 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 3 | NCT02713178 Comparator | Jun 2016 → Jun 2017 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02927379 Comparator | Jun → Dec 2016 | digestive system cancer | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT02801201 Comparator | May 2016 → Dec 2024 | — | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 3 | NCT02713230 Comparator | May 2016 → Jul 2017 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02741713 Comparator | Apr 2016 → Jun 2017 | bicipital tenosynovitis | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02652156 Comparator | Nov 2015 → Apr 2016 | neuropathy, painful | Joshua Herskovic | Terminated | No outcome recorded |
| Phase 3 | NCT02632136 Comparator | Nov 2015 → Nov 2016 | — | Mayo General Hospital, Ireland | Unknown | No outcome recorded |
| Phase 3 | NCT02574520 Comparator | Nov 2015 → Jun 2017 | — | Durect | Completed | No outcome recorded |
| Phase 3 | NCT03103100 Comparator | Oct 2015 → Jul 2019 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 3 | NCT02521831 Comparator | Oct 2015 → Dec 2017 | — | Emmett Whitaker, M.D. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02665273 Comparator | Jul 2015 → Jan 2018 | migraine disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03067896 Comparator | Jun 2015 → Mar 2017 | — | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT02658760 Background | Jun 2015 → Dec 2016 | — | Hamidreza Mahboobi | Unknown | No outcome recorded |
| Phase 3 | NCT02466022 Background | Jun → Nov 2015 | — | University of Saskatchewan | Completed | No outcome recorded |
| Phase 3 | NCT02331563 Background | Oct 2014 → Sep 2015 | — | Kırıkkale University | Withdrawn | No outcome recorded |
| Phase 3 | NCT02075411 Comparator | Mar 2014 → Feb 2015 | — | Children's Hospital of Philadelphia | Terminated | No outcome recorded |
| Phase 3 | NCT02473198 Comparator | Jan 2014 → Feb 2017 | osteoarthritis | The New England Baptist Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02444260 Comparator | Dec 2013 → Dec 2015 | — | The University of The West Indies | Unknown | No outcome recorded |
| Phase 3 | NCT03013361 Comparator | Jul 2013 → Dec 2014 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 3 | NCT01802411 Comparator | Dec 2012 → Jun 2013 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01837290 Comparator | Dec 2012 → Jan 2014 | chronic renal failure syndrome, osteoporosis | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT01538459 Comparator | Nov 2012 → Nov 2013 | disease of the tendon, rotator cuff syndrome | Lifespan | Withdrawn | No outcome recorded |
| Phase 3 | NCT01939314 Comparator | Oct 2012 → Dec 2013 | migraine disorder | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT01423292 Comparator | Aug 2011 → Mar 2012 | — | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 3 | NCT01381081 Comparator | Jul 2011 → Jan 2014 | osteoarthritis, knee | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT01073995 Comparator | Mar 2010 → Nov 2015 | radiculopathy | Horizon Health Network | Completed | No outcome recorded |
| Phase 3 | NCT00871442 Comparator | May 2009 → Mar 2010 | — | Neil Roy Connelly, MD | Withdrawn | No outcome recorded |
| Phase 3 | NCT00813111 Comparator | Nov 2008 → Feb 2009 | — | Pacira Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 3 | NCT00745290 Comparator | Aug 2008 → Jan 2009 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT00744848 Comparator | Aug 2008 → Feb 2009 | hemorrhoid | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT00678379 Comparator | Apr 2008 → Nov 2009 | — | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00658736 Comparator | Mar 2008 → Jan 2011 | chronic pancreatitis | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00547989 Comparator | Oct 2006 → Dec 2010 | breast cancer | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00398866 Comparator | Aug 2006 → Mar 2013 | osteoarthritis | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 3 | NCT00600158 Comparator | Apr 2005 → Jul 2006 | ileus | University of Virginia | Completed | No outcome recorded |
| Phase 3 | NCT00180687 Comparator | Oct 2004 → Sep 2005 | — | Imperial College London | Completed | No outcome recorded |
| Phase 4467 trials | ||||||
| Phase 4 | NCT07614802 Background | Aug 2026 → Aug 2027 expected | — | Duke University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07644923 Background | Aug 2026 → Aug 2028 expected | — | NYU Langone Health | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07632820 Background | Aug 2026 → Aug 2029 expected | — | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07097493 Comparator | Aug → Dec 2026 expected | osteoarthritis, knee | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07430085 Comparator | Jul 2026 → Jan 2028 expected | osteoarthritis, knee | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Not yet recruiting | No outcome recorded |
| Show all 467 trials opens the full record — a long page | ||||||
| Phase not applicable517 trials | ||||||
| — | NCT05785377 Comparator | Dec 2027 → Jul 2029 expected | — | Mansoura University | Not yet recruiting | No outcome recorded |
| — | NCT07624890 Comparator | Dec 2026 expected | neuroma | Ukrainian Society of Regional Anesthesia and Pain Therapy | Not yet recruiting | No outcome recorded |
| — | NCT07667439 Comparator | Jul 2026 → Feb 2027 expected | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT07429019 Comparator | Jul 2026 → Jul 2027 expected | chronic pain syndrome | Hadassah Medical Organization | Not yet recruiting | No outcome recorded |
| — | NCT07654556 Comparator | Jul 2026 → Mar 2027 expected | — | Cairo University | Not yet recruiting | No outcome recorded |
| Show all 517 trials opens the full record — a long page | ||||||
Evidence & citations 93 cited values
Every value below carries the sentence it was read from. 2,212 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bupivacaine | “patients whose labor analgesia is maintained using PIEB with low-volume bolus (6.25 mL) of a higher local anesthetic concentration solution (0.1% bupivacaine with fentanyl 2.0...” NCT03553576 ↗1899“The procedure will be completed by applying the first injection to the femoral triangle (10 ml of local anesthetic solution), the second injection to the subsartorial region...” NCT05566561 ↗ “Suprascapular nerve block with Bipuvacaine: a 50mm 22G needle (Stimuplex, BBraun) was introduced up to the suprascapular fossa, guided by ultrasound, and the location was...” NCT05778422 ↗ “After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with...” NCT02622893 ↗ “For patient undergoing total knee replacement arthroplasty, patients injected intrathecally with bupivacaine 8 mg were compared with those with bupivacaine 8 mg with 25 mcg of...” NCT01261078 ↗ “A formulation of bupivacaine, given as a single injection after surgery, that could provide adequate, continuous, and extended pain relief would greatly simplify postoperative...” NCT00485667 ↗ “The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two...” NCT06349772 ↗ “Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric...” NCT05897151 ↗ “USG with a 25G needle, Bupivacaine 0.5% 30ml with 4mg preservative free dexamethasone divided as follows into the following 5 nerves: Posterior Tibial nerve (10ml), Saphenous...” NCT05368012 ↗ “The purpose of this study is to determine whether an injection of a local anesthetic (Bupivacaine with epinephrine) in the vaginal cuff prior to closure would result in less...” NCT06719180 ↗ “Under steady state 0.2 ml kg(-1) and after 10 min 0.4 ml kg(-1) of one of the following three test solutions was administered i.v.: bupivacaine 0.125% (Group 1), bupivacaine...” PMID 19915187 ↗ Jan 2010 “Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable...” NCT03769714 ↗ “To evaluate if an injection in the retropubic space with a local acting anesthetic, Marcaine, (bupivacaine) at the time of mid-urethral sling placement will improve patients'...” NCT00746863 ↗ “standard clinical practice for TAP blocks typically involves local anesthetics like bupivacaine, which, when administered in the appropriate plane, has been shown to reduce...” NCT06925152 ↗ “Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus...” NCT03463915 ↗ “The blockage of the saphenous nerve in the adductor canal will be performed with 30 mL of local anesthetic (0.25% bupivacaine) solution with a 22 gauge 5-8 cm long block needle...” NCT05742958 ↗ “This is a prospective, single-institution, parallel-group, single-blinded, randomized-controlled, two-arm, effectiveness study comparing bupivacaine liposomal injectable...” NCT02111746 ↗ “At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will...” NCT00691795 ↗ “The "Control Arm" will receive an adductor canal catheter through which they will receive a 20 ml bolus of 0.25% bupivacaine with 1:400,000 epinephrine followed by an adductor...” NCT02991404 ↗ “An injection of 2 ml of hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 25 micrograms of...” NCT02128451 ↗ “Participants randomized to the experimental arm will receive a bilateral rectus sheath block which is additional to the standard of care (infiltration of 5mg (2mL) 0.25%...” NCT04717193 ↗ “patients received 50 ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% immediately before creation of a pneumoperitoneum and placement of...” NCT04813016 ↗ “ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated...” NCT05863221 ↗ “we propose that by injecting the uterosacral ligaments and thus the uterine nerve during robotic assisted hysterectomies with Marcaine (Bupivacaine 0.5% with epinephrine...” NCT02230735 ↗ “In both M group and B group, preemptive US guided Subcostal TAP block (Toshiba Xario, Japan) was performed on both sides using 20 ml volume (0.25 Bupivacaine in B group or 0.25...” NCT02533284 ↗ “Patients in this group will receive the standard spinal anesthetic consisting of hyperbaric bupivacaine 0.5% (15 mg) combined with an equivalent volume of normal saline (0.9%...” NCT07327879 ↗ “The anesthesiologist will direct a 22G, 80 mm needle toward the transversus abdominis fascia and inject 25 mL of 0.25% bupivacaine between the rectus abdominis and transversus...” NCT06584695 ↗ “In addition either caudal anesthetic block (0.25% bupivacaine 1 ml/kg to a maximum of 10 ml) or dorsal penile block (bupivacaine without epinephrine 10-20 ml/kg) will be...” NCT02512887 ↗ “Based on a randomized allocation, patients will receive either a caudal anesthetic block (0.25% bupivacaine, 1 ml/kg, up to a maximum of 10 ml) or a dorsal penile block...” NCT06417060 ↗ “Parallel Study to Evaluate the Pharmacokinetics, Dose Proportionality, Safety and Tolerability of GTX-101 (Bupivacaine Hydrochloride Metered Dose Spray) and Subcutaneous...” NCT05517486 ↗ “Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle...” NCT00947765 ↗ “Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1 milliliter (mL) depo methylprednisolone (a steroid) and 2 mL 0.5% bupivacaine...” NCT04504812 ↗ “DepoFoam® bupivacaine (Pacira Pharmaceuticals, Inc., San Diego, CA, USA), an extended-release liposomal bupivacaine-based analgesic, was compared with placebo for the...” PMID 21842428 ↗ Aug 2011 “This study is perfored to investigate the efficacy of preoperative lidocaine spray and lidocaine-bupivacaine mixture-soaked nasal packing for acute postoperative pain after...” NCT03733275 ↗ “DISCUSSION: A 10 mL 0.15% bupivacaine bolus in continuous adductor canal block offers comparable average knee-pain relief 6 and 12 hours after total knee arthroplasty to a...” PMID 40393775 ↗ May 2025 “In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs...” NCT01760174 ↗ “Liposomal bupivacaine, a multivesicular formulation engineered to provide sustained and controlled release of bupivacaine, has been developed to prolong analgesic duration and...” NCT07196631 ↗ “an ultrasound guided erector spinae plane catheter with initial bolus of 30 mL of 0.25% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour via programmed...” NCT06347874 ↗ “Under ultrasound guidance, the transverse process was identified, and 30 ml of 0.25% bupivacaine was injected into the fascial plane between the erector spinae muscle and the...” NCT07454304 ↗ “In the EVE group, 1 mL of a mixture containing a combination of 10 µg fentanyl and 0.25% isobaric bupivacaine was injected into the intrathecal region via a 25-G 120 mm...” PMID 40068075 ↗ Mar 2025 “Intercostal nerve block using single total administration of 20 mL EXPAREL (bupivacaine liposome injectable suspension) 266 mg (approximately 88 mg \[6.6 mL\] to each of three...” NCT01802411 ↗ “Subjects randomized to the PVB arm will have an ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine /...” NCT03471442 ↗ “Patients will receive bilateral deep parasternal plane block using, 1mg/kg of 0.25% bupivacaine on each side under ultrasound guidance. The total dose of bupivacaine amounting...” NCT06873906 ↗ “Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on...” NCT04331938 ↗ “Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique” NCT02302586 ↗ “The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.” NCT01513564 ↗ “Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the suprapatellar pouch.” NCT01923909 ↗ “The intervention involves injection of local anesthetic (0.25% bupivacaine with 1:200,000 epinephrine) under direct vision in the serratus anterior muscle plane at the end of surgery.” NCT02893384 ↗ “A 5 mL injection of 0.5% bupivacaine will be administered into the trans-obturator/levator ani sling insertion site at the end of the TVT or TVT-O procedure, prior to wound closure.” NCT07429019 ↗ “Subjects in the Experimental Group will received a 2 mL injection consisting of 1 mL of 0.5% bupivacaine (5 mg bupivacaine-HCL) and 1 mL Kenalog-40 (40 mg triamcinolone acetonide).” NCT05178485 ↗ “20 mL of local anesthetic solution (10 mL of 0.5% bupivacaine and 10 mL of 2% lidocaine) was injected bilaterally into the erector spinae plane at the T7-T8 level before incision.” NCT07057934 ↗ “Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline” NCT03176758 ↗ “Participants will be randomly allocated to receive either an ultrasound-guided femoral nerve block with 20 mL of 0.5% bupivacaine or intravenous fentanyl at a dose of 1 mcg/kg.” NCT06862154 ↗ “Group A will receive one intra-articular injection of 2 ml of solution containing 1ml of 10mg/ml Triamcinolone suspended in 1 ml of 0.5% Bupivacaine solution per affected joint” NCT01920373 ↗ “Patients will receive bilateral ultrasound-guided intramuscular quadratus lumborum block with an injection of 0.4 ml/kg bupivacaine 0.25% after induction of general anesthesia.” NCT06889987 ↗ “Intrathecal hyperbaric bupivacaine (0.5%) and a mixture of propofol (1-2 mg/kg) and fentanyl (50-100 μg/kg) were used as induction agents in the SA and GA groups, respectively” PMID 39740955 ↗ Apr 2026 “The purpose of this study is to determine whether injection of bupivacaine into the TAP is effective in the treatment of post operative pain after laparoscopic gastric bypass” NCT01308554 ↗ “G1 patients received 1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and G2 patients received 25 mg (10 ml) 0.25% bupivacaine without epinephrine.” NCT00636415 ↗ “Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively.” NCT04025606 ↗ “Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia” NCT04104204 ↗ “After mesh placement, a long-acting local anesthetic (bupivacaine hydrochloride, 0.50%) or placebo (0.9% normal saline) was injected between the mesh and the peritoneum.” PMID 26154700 ↗ Sep 2015 “Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)” NCT06593665 ↗ “Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.” NCT00756600 ↗ “Multimodal local injection of bupivacaine (Marcaine), morphine sulfate (Duramorph), ketorolac (Toradol) given at the fracture site at the time of hip fracture surgery” PMID 37199438 ↗ Sep 2023 “Bupivacaine Liposome Versus Bupivacaine for Ultrasound-Guided Suprascapular Nerve Combined With Axillary Nerve Block in Analgesia After Arthroscopic Shoulder Surgery” NCT07410182 ↗ “TAP Block in the experimental arm will be performed with 20 mL (266mg) of liposomal bupivacaine with 25 mL (5 mg/mL) of bupivacaine diluted in 55 mL of normal saline” NCT04781075 ↗ “Hydromorphone will be received intravenously using a patient controlled administration pump, as well as patient will have a continuous bupivacaine epidural infusion” NCT06559969 ↗ “A predetermined small dose of hyperbaric bupivacaine (Marcaine Spinal Heavy; Astra Zeneca, Lund, Sweden) which was prepared in1 mL tuberculin syringe was injected.” NCT02299167 ↗ “EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis” NCT01318590 ↗ “The investigators have previously utilized the On-Q® pain ball to obtain local control by continuous delivery of bupivacaine to pain fibers at the incision site.” NCT02142829 ↗ “Patients will receive either 3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose; or 3 placebo-sponges.” NCT02523599 ↗ “The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block.” NCT04445337 ↗ “The specific aim of this study is to evaluate plasma concentration of bupivacaine after intraoperative intercostal injections of 266 mg of liposomal bupivacaine” NCT03737292 ↗ “Chemical ablation is performed by injection of 10 mL of 0.25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol using a 22G FNA needle (Cook and Olympus)” NCT04801082 ↗ “Bupivacaine, a long-acting local anesthetic, is hypothesized to reduce postoperative pain when instilled into the peritoneal cavity at the end of the procedure.” NCT07098429 ↗ “The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.” NCT04258241 ↗ “Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.” NCT06422182 ↗ “Group F (fentanyl group):will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5% and 0.5 ml (25 mcg) Fentanyl and 1 ml glucose 5% with total volume of 3ml.” NCT07114263 ↗ “Patients will receive an intercostal nerve block with a mixture of liposomal bupivacaine and bupivacaine hydrochloride immediately after lung transplantation.” NCT07641647 ↗ “Group A will receive 0.07 mg/cm of 0.5% Hyperbaric Bupivacaine in conjunction with 2 mg (0.5 ml) of preservative-free Dexamethasone administered intrathecally” NCT07363941 ↗ “i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision.” NCT06580327 ↗ “the prilocaine group underwent spinal anaesthesia with 60 mg intrathecal prilocaine; and the bupivacaine group received 12.5 mg intrathecal heavy bupivacaine.” PMID 33428221 ↗ Jan 2021 “Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate).” NCT05697276 ↗ “Our study will compare Exparel (bupivacaine liposome) with Ropivacaine continuous infusion for post-operative pain scores in total shoulder surgery patients.” NCT03739021 ↗ “ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections” NCT06213454 ↗ “0.25% bupivacaine, with 10 mL (25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the surgical procedure.” NCT02933814 ↗ “Solutions contain either 0.3% Ropivacaine, 1% Procaine, 0.5% Lidocaine, 0.25% Bupivacaine, or a mixture of 0.25% Bupivacaine and 2% Lidocaine in a 9:1 ratio.” NCT06617065 ↗ “3ml intrathecal starting at a mass of 10 µmol bupivacaine, levobupivacaine or ropivacaine by a combined spinal-epidural analgesia technique (groups A, B, C).” NCT01201213 ↗ “30 mL of 0.25% Bupivacaine will be injected into the plane between the Serratus Posterior Superior muscle and the intercostal muscles at the scapular level.” NCT07436806 ↗ “Liposomal bupivacaine, trade name Exparel, was recently introduced as an alternative to drugs such as bupivacaine, but boasting a longer duration of action.” NCT06139666 ↗ “Two cc containing 40 mg of triamcinolone acetonide with 5 mg bupivacaine will be infused into the upper joint space after the TMJ arthrocentesis procedure.” NCT04731233 ↗ “will include 30 patients: each one will receive 2.5 mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline, 10 minutes before skin incision” NCT04838379 ↗ “Phase 3 Study Comparing Transversus Abdominis Plane Block After Caesarian Section Usin Bupivacaine 0.5% vs. Bupivacaine 0.25% vs. Placebo (Normal Saline).” NCT01986049 ↗ “Therefore, we designed a prospective randomized controlled trial to compare the analgesic efficacy of combining magnesium sulfate with bupivacaine in QLB.” NCT06301789 ↗ “All patients in the study group will receive bilateral pudendal nerve block at the end of surgery, with help of landmark technique, using 0.5% bupivacaine” NCT05022160 ↗ “Betamethasone Sodium Phosphate/Acetate 5.7 mg/ml Injectable is a particulate corticosteroid and is used with the local anaesthetic bupivacaine 0.5% (1ml).” NCT03240783 ↗ “The ITM group received morphine, clonidine and bupivacaine intrathecally; the EDA group had an epidural infusion of bupivacaine, adrenalin and fentanyl.” PMID 30837253 ↗ Mar 2019 “Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml” NCT04426058 ↗ “hyperbaric bupivacaine 0.5% 1.8 ml mixed with intrathecal morphine 100 µg (M100), intrathecal morphine 50 µg (M50), or intrathecal fentanyl 25 µg (F25)” PMID 42332552 ↗ Jun 2026 “A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration.” NCT04005859 ↗ “Comparative Study Between Dexmedetomidine and Fentanyl as an Adjuvant to Intraarticular Bupivacaine for Postoperative Analgesia after Knee Arthroscopy.” PMID 34704709 ↗ Nov 2021 “10 mg 0.5% bupivacaine + 20 mcg Fentanyl injection will be applied using a 26 Gauge pencil point needle through the L3-L4 or L4-L5 intervertebral space” NCT05965544 ↗ “spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h” NCT02711072 ↗ “ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side” NCT04531215 ↗ “Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization” NCT03182933 ↗ “a total of 4 mL of local anesthetic solution consisting of 2 mL of 0.5% bupivacaine and 2 mL of 2% lidocaine (Aritmal) will be injected on each side.” NCT07608861 ↗ “Ganglion Impar Block using Triamcinolone Acetate (40 mg) and Bupivacaine (0.25%) administered with a 22G Spinal Needle under Fluoroscopic Guidance).” NCT06754033 ↗ “Liposomal bupivacaine is a novel formulation of bupivacaine designed for slow diffusion of a single dose of local anesthetic over a 72-hour period.” PMID 27159290 ↗ Apr 2016 “Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.” NCT02411149 ↗ “Bupivacaine 2% - a local anesthetic that binds voltage-gated sodium channels and blocks sodium influx into nerve cells preventing depolarization.” NCT02485145 ↗ “Each patients group will recieve a type of block by injecting 20 ml of 0.25% bupivacaine on each side in patients undergoing open cholecystectomy” NCT06410911 ↗ “Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision” NCT05105997 ↗ “A single injection of 30 ml of bupivacaine 0.25% will be applied into the interfacial plane between the rhomboid major and intercostal muscles.” NCT05452369 ↗ “All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive” NCT03824665 ↗ “5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)” NCT03479216 ↗ “intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline) will be done” NCT04525274 ↗ “Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.” NCT06499181 ↗ “In the intrathecal morphine group, 100 micrograms of morphine (0.1 mL) will be added to the 12 mg of intrathecally administered bupivacaine.” NCT06612424 ↗ “Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).” NCT06216197 ↗ “30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.” NCT03794882 ↗ “Patients will receive16 ml bupivacaine 0025% will be administered, and4 ml of this solution will be placed at each of the 4 target nerves.” NCT05269095 ↗ “Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr” NCT04541719 ↗ “Group D: patients will receive 3 mL volume of 0.5% hyperbaric bupivacaine and 4 µg dexmedetomidine in 0.5 mL of normal saline intrathecal” NCT07035223 ↗ “Intervention group will receive 30 ml of a 50/50 mixture of isobaric bupivacaine 0.5% and lidocaine 1%, containing 8 mg of dexamethasone.” NCT07313553 ↗ “The first group received 0.5% bupivacaine, the second group received 0.375% bupivacaine, and the third group received 0.25% bupivacaine.” PMID 39355572 ↗ Jun 2024 “20cc of 2% lidocaine with 1:200,000 epinephrine + 20 cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve” NCT02280291 ↗ “the first group (dexmedetomidine5 μg group) will be received 2mL (10 mg) of heavy bupivacaine plus 5 μg of dexmedetomidine intrathecally” NCT05351489 ↗ “Two 20 mL syringes were prepared after preparing a local anesthetic concentration of 1.5 mg/kg of 0.5% bupivacaine to 40 mL with saline.” NCT02645903 ↗ “the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.” NCT06377605 ↗ “The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)” NCT04212949 ↗ “Epidural medication will be the same in both groups and will consist of bupivacaine 0,05% with fentanyl 2 µg/mL and adrenaline 2 µg/mL.” NCT05534945 ↗ “A single 14 mL dose of HTX-011 containing 400 mg bupivacaine and 12 mg meloxicam will be applied intraoperatively to the surgical site.” NCT07216586 ↗ “Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol” NCT04457986 ↗ “Patients received superficial cervical plexus block with 1 ml of normal saline with 7ml bupivacaine 0.25% per side without adjuvants.” NCT07057739 ↗ “Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block” NCT05692167 ↗ “The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)” NCT04485273 ↗ “0.5% hyperbaric bupivacaine will be administered intrathecally for spinal anesthesia in patients undergoing cystoscopic procedures.” NCT07590544 ↗ “Magnesium Sulphate (Group M): 50 mg magnesium sulphate added to 12.5 mg of 0.5% hyperbaric bupivacaine, administered intrathecally.” NCT07113782 ↗ “The mean ± standard deviation maximum observed plasma concentration (C max) of bupivacaine after a single dose was 129 ± 47 ng/mL.” PMID 28120158 ↗ Mar 2017 “Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.” NCT06034873 ↗ “2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity” NCT02820610 ↗ “Marcaine hydrochloride (bupivacaine) without epinephrine 0.5% was chosen for this study because this was used in previous studies” NCT06842771 ↗ “Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia.” NCT02632136 ↗ “Patients will receive general anesthesia (GA) with ultrasound guided serratus anterior plane block 0.5 ml/kg 0.25% bupivacaine.” NCT06862518 ↗ “Exparel is a formulation of liposomal bupivacaine that is reported to allow local anesthesia for up to 72 hours post injection.” NCT02499159 ↗ “Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25\~0.5% lidocaine, 0.125% bupivacaine)” NCT01845532 ↗ “Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.” NCT02951806 ↗ “Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height” NCT03849508 ↗ “using 20 ml bupivacaine 0.25% that will be injected for each side ensuring not to exceed the maximal 2 mg/kg bupivacaine dose.” NCT06870383 ↗ “Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine” NCT04650737 ↗ “IPACK block with 20 mL of 0.25% Bupivacaine injected into the Interspace between the Popliteal Artery and Capsule of the Knee” NCT05286307 ↗ “%0.25 bupivacaine) will be performed Drug: Tramadol 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline” NCT07096765 ↗ “Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.” NCT01846221 ↗ “Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline.” NCT03737604 ↗ “The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.” NCT04892420 ↗ “15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.” NCT02052180 ↗ “all patients receive spinal anesthesia with a solution of 2 ml hyper-baric bupivacaine 0.5% (10 mg) and 3 μg of sufentanil” NCT07377630 ↗ “Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration” NCT04160936 ↗ “An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.” NCT02502591 ↗ “Following confirmation of the correct position of the needle, 30 mL %0.25 bupivacaine will be administered for the block.” NCT07278050 ↗ “bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively” NCT05069311 ↗ “Medications used during the procedure include 0.75% bupivacaine with or without 1 mg of preservative free dexamethasone.” NCT06621329 ↗ “It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg.” NCT06155903 ↗ “HTX-011 (bupivacaine and meloxicam in Biochronomerpolymer technology), an extended-release, dual-acting local anesthetic” PMID 31113830 ↗ May 2019 “The intervention group will receive bupivacaine injection guided by ultrasound at the location of the stellate ganglion.” NCT05656170 ↗ “Following this, the total volume of 40 ml of 0.25% bupivacaine will be instilled, creating a meniscus between the planes” NCT06721039 ↗ “30ml total volume of 0.25 plain bupivacaine 1.5mg/kg with lidocaine 1% 3mg/kg with 8mg dexamethasone in group A patients” NCT06131593 ↗ “Patients will receive ultrasound-guided rectus sheath block (20 ml bupivacaine 0.25%) bilaterally at the end of surgery.” NCT06837532 ↗ “will receive an ultrasound guided PENG block with 20 mL of 0.5% bupivacaine followed by cryoablation of the PENG nerves.” NCT06278987 ↗ “Intrathecal anesthesia is with bupivacaine 12.5-15.0 mg, morphine 0.2 mg and clonidine 30 µg (total volume (3.2-3.7 mL).” NCT01604382 ↗ “Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine.” NCT05004636 ↗ “Patients will receive rectus sheath block (20 ml bilaterally, bupivacaine 0.25%) after induction of general anesthesia.” NCT06837506 ↗ “Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution” NCT02571283 ↗ “Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg” NCT05191745 ↗ “The intercostal infiltration with 30 ml of 0.25% concentration of bupivacaine will be performed by the surgical team.” NCT05972122 ↗ “Injection of 3 mcg of dexmedetomidine and 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.” NCT05099055 ↗ “1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.” NCT04109885 ↗ “Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted.” NCT05444751 ↗ “5cc of 0.5% bupivacaine will be injected into both right and left occipital nerves using a 2.5 inch 25 gauge needle.” NCT03951649 ↗ “10mg morphine in 5ml normal saline + 10ml of 0.25% bupivacaine ( total volume 15 ml) were injected intra-articularly” NCT04790292 ↗ “At the end of the surgery patients receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.” NCT03248648 ↗ “Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.” NCT03326999 ↗ “One side with Marcaine (Bupivacaine HCL) 0.5% 5 mg / mL Injection,opposite side without injection of any anesthetic.” NCT03479996 ↗ “In the D1 group, patients were administered 20 mL of 0.25% isobaric bupivacaine with 0.5 mcg/kg of dexmedetomidine.” NCT06703229 ↗ “Bilateral lateral Quadratus Lumborum block using 20 ml of 0.25% bupivacaine each injection as preemptive analgesia.” NCT03879980 ↗ “intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%” NCT01074567 ↗ “Recently, liposomal bupivacaine (LB) (Exparel) was approved for single shot interscalene administration by the FDA.” NCT03822182 ↗ “After confirming the block location, 10 ml of 0.25% concentration marcaine (bupivacaine) will be used (bilateral).” NCT06285773 ↗ “Group B: The patients will receive 20 ml of 0.5% bupivacaine plus 5 ml 0.9% normal saline with total volume 25 ml.” NCT04429893 ↗ “Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon” NCT02417987 ↗ “Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA)” NCT03743194 ↗ “spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg)” NCT01312415 ↗ “In the application, a 22G 10 cm needle is used in the form of 20 ml 0.25% bupivacaine + 2.0 μg/mL of epinephrine.” NCT05943080 ↗ “30mL of 0.5% bupivacaine with 100 mcg clonidine, 0.3 mg buprenorphine, and 4 mg dexamethasone will be injected.” NCT05824832 ↗ “Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.” NCT06668220 ↗ “Participants will get a QL block using 30cc Bupivacaine bilaterally in quadratus lumborum muscle (60cc total).” NCT05979493 ↗ “Intraperitoneal infiltration of 20ml of 0.25% Bupivacaine will be done at the end of procedure by the surgeon.” NCT07409688 ↗ “Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml” NCT04656821 ↗ “single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side.” NCT02996227 ↗ “intrathecal bolus of 3ml bupivacaine 0.5% (15mg) plus 10 micrograms dexmedetomidine at 2-3 or 3-4 spinal level” NCT05262166 ↗ “10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml” NCT04202887 ↗ “15 mL of 0.25% Bupivacaine block of the saphenous nerve injected under ultrasound guidance via adductor canal.” NCT06952556 ↗ “Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose.” NCT03395600 ↗ “a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine” NCT03885804 ↗ “1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space.” NCT04186624 ↗ “a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000 will be slowly injected” NCT02065947 ↗ “Ultrasound guided ESP block will perform with 15 ml bupivacaine+ 5 ml lidocaine at the T10 level bilaterally.” NCT04148729 ↗ “adductor canal block with continuous infusion of 0.25% bupivacaine 3.5 ml per hour for 2 days postoperatively” NCT05518513 ↗ “10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid” NCT03600454 ↗ “The local anesthetic used in all cases was a mixture of 10 ml of 2% xylocaine and 10 ml of 0.5% bupivacaine.” NCT07299877 ↗ “Dexmedetomidine 3 µg (n=27) or normal saline (n=27) intrathecally with 6 mg of 0.5% hyperbaric bupivacaine.” PMID 23727917 ↗ 2013 “an injection of Exparel (bupivacaine liposome injectable suspension), 20cc of 1.3% Exparel, to total 100cc.” NCT02808728 ↗ “Bupivacaine 0.3% \[or ropivacaine 0.5%\] infusions for 7 days via femoral and sciatic perineural catheters” NCT03461120 ↗ “A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.” NCT03408184 ↗ “Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.” NCT06658054 ↗ “Liposomal Bupivacaine (Exparel®) or the control injected into the transversus abdominis plane bilaterally.” NCT04655339 ↗ “Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.” NCT01733472 ↗ “Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)” NCT02103543 ↗ “patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia” NCT04926454 ↗ “Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug” NCT01367418 ↗ “20 ml 0.25% Bupivacaine along with 0.5 Mcg/kg of Dexmedetomidine will be given in TAPP block bilaterally” NCT07508202 ↗ “A total of 30 ml of 0.25% bupivacaine was administered deep to erector spinae muscle (ESM) bilaterally.” NCT06721832 ↗ “Caudal block will be performed with 0.75ml/kg of 0.25% bupivacaine containing 1 mic/kg dexmedetomidine.” NCT05233683 ↗ “The regimen consists of Bupivacaine 0.375% with the adjuvant Dexmedetomidine at a dose of 0.5 mcg/kgbw.” NCT07274670 ↗ “20 mL Liposomal bupivacaine (Exparel, 266 mg) will be administered in the popliteal and saphenous block” NCT06465992 ↗ “The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine in tap block” NCT06624319 ↗ “injection of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000” NCT06490614 ↗ “intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)” NCT04859764 ↗ “7.5 mg Bupivacaine hydrochloride (0.5% heavy Marcaine) will be used on spinal anesthesia. (each group)” NCT06293404 ↗ “A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared.” NCT01688362 ↗ “Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.” NCT02369523 ↗ “A solution containing fentanyl 2 mcg/mL and bupivacaine 0.625 mg/mL at an infusion rate of 0.5 ml/hr.” NCT07091123 ↗ “infiltration of the hip joint with hyaluronic acid, with a corticosteroid or with 0.125% bupivacaine.” PMID 21080920 ↗ Nov 2010 “bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.” NCT05344495 ↗ “A Randomized Controlled Trial of Liposomal Bupivacaine Parasternal Intercostal Block for Sternotomy.” PMID 30170012 ↗ Aug 2018 “Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.” NCT03859102 ↗ “12.5 mg ofhyperbaric bupivacaine (2.5 mL 0.5%) and 15 μg of fentanyl will be injected intrathecally” NCT07514130 ↗ “Bupivacaine, Dexamethasone, Epinephrine for hernia patients receiving abdominal wall reconstruction” NCT07518238 ↗ “Intrathecal injection of 100 µg morphine plus 20 mg hyperbaric bupivacaine (in spinal anesthesia).” NCT06882369 ↗ “a mixture of 0.5 % bupivacaine (10 ml) and 2 % lidocaine (10 ml) will be injected into the muscle” NCT06462573 ↗ “The LA used for the blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg.” NCT03731221 ↗ “Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS. 30mL per side)” NCT05972018 ↗ “will have PENG block with 2mg magnesium sulphate 10% as an adjuvant to 20mg of bupivacaine 0.25%” NCT06180031 ↗ “Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution.” NCT05898087 ↗ “An injection of 1-2 ml bupivacaine 0.5% will be placed around the affected branch of the neuroma” NCT05695339 ↗ “Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine” NCT03119038 ↗ “Group H will receive 10 ml 0.25 % bupivacaine he technique will be repeated on the opposite side” NCT06621836 ↗ “dexamethasone 8mg, methylprednisolone 80mg and bupivacaine 5ml 0.25%, intra articular injection” NCT07489521 ↗ “Admixture bupivacaine 0.5 % 10 cc with Bupivacaine Liposome Injectable Suspension 10cc total 20” NCT06274008 ↗ “Bupivacaine 0.5% administered after ablation as part of the post-procedural injection mixture.” NCT07475689 ↗ “Patients received bilateral ultrasound-guided ESPB using 20 mL bupivacaine 0.25% on each side.” NCT06695858 ↗ “standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.” NCT03420638 ↗ “Bupivacaine should reduce postoperative pain but it has relatively shorter duration of action.” NCT02969187 ↗ “The injection contained 150mg bupivacaine (3mg/mL), 60mg ketorolac(1.2mg/mL) and 1mg morphine.” NCT06630520 ↗ “0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.” NCT03243032 ↗ “SGB) with bupivacaine, a local anesthetic, is an effective and safe non-hormonal intervention” NCT02907983 ↗ “After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.” NCT05972083 ↗ “giving the longer-acting local anesthetic liposomal bupivacaine prior to closing the sternum” NCT04585867 ↗ “Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.” NCT02341079 ↗ “Group LWI+IPLA will given 30 ml %0,5 bupivacaine+%2 lidocaine infiltration and instillation” NCT05405049 ↗ “Injection with 10 mls 0.5% bupivacaine hydrochloride and • 40 ml saline around the tendon.” NCT02839577 ↗ “bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml” NCT00805298 ↗ “20 milliliter (mL) EXPAREL with 20mL bupivacaine hydrochloride (HCL) 0.5% will be expanded.” NCT06619340 ↗ “Parasternal block group, bilateral parasternal block was performed using 0.25% bupivacaine.” NCT06893601 ↗ “consists of patients receiving Serratus anterior plane block using Bupivacaine + Ketamine.” NCT05802979 ↗ “Standard single-shot anesthesia consists of bupivacaine 0.25% with epinephrine 1:400,000.” NCT05019638 ↗ “Hyperbaric bupivacaine 0.5% will be administered at the dose of age divided by 5 (in ml).” NCT06801600 ↗ “30 participants had received 1 mL/kg 0.25% bupivacaine. Post operative pain was assessed.” NCT07140627 ↗ “Group A : will receive bupivacaine 0.25% + dexmedetomidine 1 mic/kg, total volume (20 ml)” NCT06294665 ↗ “subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected.” NCT02453360 ↗ “Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine” NCT02322372 ↗ “A solution (10 ml) containing 1.5 mg/ml bupivacaine and 10 µg/ml fentanyl was prepared.” NCT05101291 ↗ “isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected.” NCT01477190 ↗ “0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine” NCT03199170 ↗ “Standardized spinal mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.” NCT06418308 ↗ “20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.” NCT05261672 ↗ “Normal saline 2 ml will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump.” NCT05323214 ↗ “We will perform M-TAPA with totally 30 ml (15 ml for each side) of %0,25 bupivacaine.” NCT05179629 ↗ “preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.” NCT02409498 ↗ “We will perform M-TAPA with totally 40 ml (20 ml for each side) of %0,25 bupivacaine.” NCT05199922 ↗ “2.5 mL 0.5% hyperbaric bupivacaine + 5 µg dexmedetomidine (0.5 mL), total volume 3 mL” NCT07326397 ↗ “Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol.” NCT04809935 ↗ “The patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally” NCT06319859 ↗ “ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine” NCT03277599 ↗ “PCB with bupivacaine or saline with regard to the highest and lowest pain intensity” PMID 26573530 ↗ Nov 2015 “using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device” NCT04466826 ↗ “15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine” NCT06837844 ↗ “BupiZenge is a lozenge that dissolves slowly in the mouth and contains bupivacaine.” NCT07672236 ↗ “Erector spinae plane block (ESPB) using multilevel injections of bupivacaine 0.25%.” NCT06884852 ↗ “0.5% bupivacaine (0.3 ml∙kg-1) was then injected after a negative aspiration test.” NCT04355468 ↗ “flow rate of 2ml/hour of 0.25% bupivacaine diluted in accordance to patient weight” NCT00884650 ↗ “Bupivacaine hydrochloride is a commonly used local anesthetic in spinal anesthesia” NCT03230474 ↗ “300-mg bupivacaine (three INL-001 100-mg bupivacaine HCl collagen-matrix implants)” PMID 30467808 ↗ Nov 2018 “plain or heavy Bupivacaine hydrochloride 10 mg (2 mL) injected in the spinal canal” NCT05706844 ↗ “Injection of Bupivacaine 0.5% 20 ml into the thickness of the right abdominal wall” NCT03532906 ↗ “PNB will be performed with 0.5% bupivacaine and 10cc will be injected bilaterally.” NCT04171050 ↗ “Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery.” NCT05763667 ↗ “a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected” NCT03408483 ↗ “They will receive 20 mg of 0.5% hyperbaric bupivacaine plus 25 microgram fentanyl” NCT06550180 ↗ “Up to a maximum of 10mL of 0.5% bupivacaine infiltration in the buccal graft site” NCT05300685 ↗ “20 ml 0.25% plain bupivacaine (10ml 0.5% bupivacaine added to 10ml normal saline)” NCT06871033 ↗ “irrigation analgesia by 5 ml bupivacaine 0.50% plus 20 ml normal saline (Group N)” NCT07370181 ↗ “injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side” NCT04614259 ↗ “20 ml of 0.25% bupivacaine plus 5 ml of normal saline containing 250 mg of MgSO4” NCT06166108 ↗ “30ml of Exparel ((bupivacaine liposome injectable suspension) 1.3% ( 13.3mg/ml))” NCT02274077 ↗ “The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.” NCT03138577 ↗ “inject 20 mL (5mL lidocaine 2% and 15 mL bupivacaine 0.25%) at each level of T4” NCT04425447 ↗ “with 7.5mg of hyperbaric bupivacaine was given for a patient 18-75 years of age” NCT05257941 ↗ “Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg.” NCT06684535 ↗ “Control patients will have a TAP block with 5 cc of bupivacaine on both sides.” NCT03294109 ↗ “A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).” NCT05630404 ↗ “medications such as Gabapentin, Tylenol, Meloxicam, Bupivacaine, or Ketorolac.” NCT04176783 ↗ “Bupivacaine will be used as the main local anesthetic medication in the study.” NCT03730714 ↗ “7.5 mg (low dose) hyperbaric bupivacaine 0.5% (Marcaine®, AstraZeneca, Sweden)” NCT06382220 ↗ “10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)” NCT04047446 ↗ “Both groups will receive port site infiltration with bupivacaine 0.25% 20 ml.” NCT06343753 ↗ “Group 1: patient controlled epidural analgesia (PCEA) with bupivacaine 1mg/mL” NCT01074190 ↗ “Lower extremity peripheral nerve block without Exparel: 0.25-0.5% bupivacaine” NCT05494645 ↗ “patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 4μg)” NCT07051512 ↗ “Patients received vastus lateralis nerve block with 5 ml of bupivacaine 0.5%.” NCT06809842 ↗ “5 mic dexmedetomidine will be given intrathecally added to 2.5 mg bupivacaine” NCT06823349 ↗ “addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia” NCT01075490 ↗ “A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).” NCT03413163 ↗ “All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine” NCT02197273 ↗ “the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done.” NCT04314505 ↗ “Thoracolumbar Interfascial Plane Block using Bupivacaine and dexmedetomidine” NCT06690021 ↗ “20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine” NCT02741713 ↗ “second group will receive the caudal block, we use bupivacaine 0.5 mg / kg.” NCT06427174 ↗ “a dose of 0.25% bupivacaine (Buvasin %5 flakon) 20ml will be injected here.” NCT06084403 ↗ “Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system” NCT02478372 ↗ “1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty” NCT03303794 ↗ “Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space.” NCT03240055 ↗ “Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection 30mL” NCT06350981 ↗ “will receive bupivacaine 0.25% (3ml) + normal saline, total volume (5 ml).” NCT07380139 ↗ “Bupivacaine 7.5mg (1.5ml) + fentanyl 25mcg in unilateral spinal anesthesia” NCT07262398 ↗ “0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine” NCT03480607 ↗ “Lignocaine and Bupivacaine are two commonly used local anesthetic agents.” NCT00950625 ↗ “Thereafter, 2 ml of bupivacaine 0.5% will be injected to block the nerve.” NCT03762343 ↗ “Bupivacaine is a local anesthetic commonly used via caudal epidural route” NCT05717374 ↗ “an injection of 10cc bupivacaine (plus \~1cc epinephrine and bicarbonate)” NCT03867539 ↗ “20ml of 0.25% bupivacaine will be injected in each side of the TAP block” NCT03060070 ↗ “local anesthetic (ropivacaine 0.2%, 2.0 mL or bupivacaine 0.25%, 2.0 mL)” NCT07431944 ↗ “Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL” NCT03638011 ↗ “different anaesthetic substances with a local action (e.g. bupivacaine)” NCT02818985 ↗ “participants will be infiltrated with only bupivacaine around the wound” NCT06076707 ↗ “10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected” NCT04160598 ↗ “12.5 mg (2.5 mL) of 0.5% hyperbaric bupivacaine + 5 µg dexmedetomidine” NCT07395271 ↗ “Bupivacaine 9 mg intrathecal single shot injection at start of surgery” NCT00537472 ↗ “6ml hyperbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline” NCT03312959 ↗ “0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL” NCT03780478 ↗ “Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline.” NCT00992082 ↗ “Patients will receive 20 ml 0.25% bupivacaine on each side TAB block.” NCT05323565 ↗ “regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)” NCT03453151 ↗ “The combination contains 0.25% bupivacaine hydrochloride (2.5 mg/mL)” NCT06456255 ↗ “the drug mix included lidocaine, bupivacaine and water for injection” NCT02245126 ↗ “30 mL of 0.25% bupivacaine will be injected as the local anesthetic.” NCT06773780 ↗ “bilateral ESP block will be injected with 20 ml of 0.25% bupivacaine” NCT04749095 ↗ “3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade” NCT05792774 ↗ “30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration” NCT03395912 ↗ “Bupivacaine is a local anesthetic agent commonly used in ESP block.” NCT05855798 ↗ “Intraoperative injection of 0.25% bupivacaine at each incision site” NCT06709716 ↗ “Intrapleural nebulization of bupivacine (10 ml of bupivacaine 0.5%)” NCT05282251 ↗ “transversus abdominus plane block using 40 ml of bupivacaine 0.25%” NCT04623632 ↗ “20 ml of 0. 25% bupivacaine plus one mL normal saline bilaterally.” NCT03746418 ↗ “We will carry out the TAP block using 0.5 ml/ kg bupivacaine 0.25%” NCT04539314 ↗ “Epidural anesthesia, with a constant infusion of 0.25% bupivacaine” NCT05844800 ↗ “50 mg bupivacaine hydrochloride 0.5% (AstraZeneca, Cenexi, France)” NCT05324995 ↗ “A total of 20ml bupivacaine 0.25% are then injected into the ESP.” NCT04110210 ↗ “less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000” NCT03408340 ↗ “A 20 ml of 0.25% plain bupivacaine will be injected on each side.” NCT05475561 ↗ “10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy)” NCT02716129 ↗ “using 20 ml Bupivacaine 0.25% by an experienced anesthesiologist” NCT06362915 ↗ “7.5 mg plain bupivacaine (Astra) will be injected intrathecally.” NCT00119184 ↗ “0.25% bupivacaine injection in 6 different locations in abdomen.” NCT02007096 ↗ “A single betamethasone and bupivacaine intra-articular injection” NCT01381081 ↗ “A total of 25 ml bupivacaine 0.5% will be injected into the ESP.” NCT04118101 ↗ “40 mls of 0.255 bupivacaine will be infiltrated at skin incision” NCT03077581 ↗ “ESPB using local anesthetic 20 ml 0.25% bupivacaine on each side” NCT06957574 ↗ “Hyperbaric bupivacaine 10-15mg plus intrathecal morphine 100mcg” NCT03518463 ↗ “Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine.” NCT05292677 ↗ “One receiving ropivacaine, one receiving liposomal bupivacaine.” NCT04801368 ↗ “30 ml of bupivacaine 0.25% solution will be used for the block.” NCT05905510 ↗ “Femoral Nerve Block with 40ml bupivacaine plus 0.5% epinephrine” NCT01911949 ↗ “HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.” NCT03695367 ↗ “Group B (Blockade with Bupivacaine): 30 mL bupivacaine (0.25%)” NCT07081581 ↗ “ultrasound-guided (USG) ACB with bupivacaine and dexamethasone” NCT04715152 ↗ “In group A intraperitoneal bupivacaine is used for pain relief” NCT07650760 ↗ “10 ml of 5% bupivacaine (Carbostesin®) was used for each side.” NCT00472446 ↗ “Injection of 30 mL local anesthetic solution bupivacaine 0.25%” NCT07037992 ↗ “the local anesthetic bupivacaine 0.5% into each affected disc” NCT04735185 ↗ “The eutectic mixture of lidocaine + prilocaine + bupivacaine.” NCT00932542 ↗ “using 0.25% bupivacaine (0.5 mL/kg) before surgical incision.” NCT07301528 ↗ “Exparel is such a compound that slowly releases bupivacaine.” NCT02607579 ↗ “2 mL of a 50:50 mixture of 2% lidocaine and 0.5% bupivacaine” NCT01670825 ↗ “20 ml solution containing 0.25% bupivacaine + normal saline” NCT07182110 ↗ “Bilaterally inject (5ml) bupivacaine 0.5% for each segment.” NCT03437213 ↗ “(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).” NCT03482947 ↗ “0.1% Bupivacaine and 2microgram\\ml Fentanyl every one hour” NCT06494280 ↗ “Intrathecal injection of bupivacaine, fentanyl and morphine” NCT06570343 ↗ “intrathecal tramadol 20mg with Hyperbaric 0.5% bupivacaine” NCT07294352 ↗ “Direct injection of 0.25% bupivacaine into surgical wounds” NCT04426500 ↗ “12 mg of isobaric "Bupivacaine 0.5%", "Bucaine®," (2.4 ml)” NCT06769737 ↗ “Preoperative Bupivacaine 0.5%, perineurally as single shot” NCT01303120 ↗ “liposomal bupivacaine 1.3% (260 mg) will be administered.” NCT02178553 ↗ “patients will be injected with 20 cc of 0.25% Bupivacaine” NCT05256056 ↗ “intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2” NCT01291186 ↗ “group administered Ultrasound guided STB with bupivacaine” NCT07046325 ↗ “20 ml of 0.25% Bupivacaine will be given at incision site” NCT05480111 ↗ “Bupivacaine was used for postoperative analgesia block.” NCT06116409 ↗ “A total of 10 ml of 0.25% bupivacaine will be injected.” NCT03450226 ↗ “TAP block with local anesthetic: Bupivacaine 0.25% 10ml” NCT07558226 ↗ “Injection bupivacaine 0.25% used as a local anesthetic.” NCT03734848 ↗ “injected 10 mL of 0.1% bupivacaine with 100 Botox units” NCT05099835 ↗ “bupivacaine 0.25% + morphine 5 mg in total volume 10 ml” NCT04033471 ↗ “dexamethasone + plain Bupivacaine injected epidurally.” NCT03231215 ↗ “a dose of 0.25% bupivacaine 20ml will be injected here” NCT04189640 ↗ “Drugs used are Bupivacaine 0.25% with volume of 25 ml.” NCT06750627 ↗ “30 ml of 0.25% concentration bupivacaine will be used” NCT06866054 ↗ “Bupivacaine(scalp block) R/A 20ml 0.5% Postoperative” NCT05474040 ↗ “EXPAREL (bupivacaine liposome injectable suspension)” NCT01509638 ↗ “20 ml of 0.25% Bupivacaine in each site of injection” NCT05369468 ↗ “spinal anesthesia with hyperbaric bupivacaine 10 mg” NCT05525819 ↗ “using 20 mL 0.25% bupivacaine and 21 G block needle” NCT03543202 ↗ “15cc 0.25% of Bupivacaine + Dexamethasone 8 mg 2cc” NCT07049835 ↗ “10 ml of bupivacaine 0.5 % mixed with 10 ml saline” NCT02122510 ↗ “20cc of bupivacaine 0.25% will be injected slowly” NCT03422354 ↗ “20 mL of 0.25% bupivacaine will be administered” NCT06910696 ↗ “20 mg isobaric bupivacaine + 1 ml normal saline” NCT03731468 ↗ “Erector spinae thoracic block with bupivacaine” NCT05521789 ↗ “lidocaine 1% and bupivacaine 0,5% 1:1 mixture” NCT03454789 ↗ “20 ml bupivacaine 0.5% + 20 ml normal saline.” NCT03967392 ↗ “0.25% bupivacaine with epinephrine 1:200 000.” NCT06945263 ↗ “Bupivacaine is a well-known local anesthetic.” NCT02067078 ↗ “10ml of 0.125% isobaric bupivacaine injected” NCT05810012 ↗ “Long-Acting Liposomal Bupivacaine (Exparel®)” NCT04826484 ↗ “20 mg bupivacaine intrathecal administration” NCT06082232 ↗ “20 mcg fentanyl in 10 mL 0.125% bupivacaine” NCT03120780 ↗ “bupivacaine 0.25% in a dose of (0.5 ml / kg” NCT06183073 ↗ “20 ml of 0.25% bupivacaine will be injected” NCT07610070 ↗ “Drug:Bupivacaine 0.25% Injectable Solution” NCT04768764 ↗ “Bupivacaine liposome injectable suspension” NCT02353754 ↗ “PIFB done with bupivacaine and epinephrine” NCT05676814 ↗ “bupivacaine liposome injectable suspension” NCT04002089 ↗ “Bupivacaine Liposome Injectable Suspension” NCT07222748 ↗ “20 ml of bupivacaine 0.25% paravertebrally” NCT02935933 ↗ “0.5% bupivacaine with epinephrine (2.25mL)” NCT04951128 ↗ “Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.” NCT03319563 ↗ “10 ml of liposomal bupivacaine (133 mg)” NCT03827291 ↗ “40 mL of bupivacaine/lidocaine mixture” NCT04336917 ↗ “20ml of 0.25% bupivacaine inTAP block” NCT07482709 ↗ “mixture of bupivacaine and sufentanil” NCT04755712 ↗ “Administration of bupivacaine 2.5 mg.” NCT01991743 ↗ “using isobaric bupivacaine 0.5% 50 mg” NCT06451705 ↗ “10 mg hyperbaric Bupivacaine ( 2ml )” NCT05474001 ↗ “injection of 30 ml bupivacaine 0.25%” NCT06519708 ↗ “local anesthetic (0.25% bupivacaine)” NCT03187080 ↗ “Drug:Caudal bupivacaine 0.25% 1ml/kg” NCT02416063 ↗ “4 ml of hyperbaric bupivacaine 0.5%” NCT03276325 ↗ “0.5% hyperbaric Bupivacaine 2.2 ml” NCT07094802 ↗ “0.25% bupivacaine with epinephrine” NCT04530149 ↗ “with 20mL of bupivacaine 0.125 %.” NCT05671081 ↗ “300 mg bupivacaine/9 mg meloxicam” NCT03907176 ↗ “bupivacaine 0.75% 1.6 mL (12mg)” NCT01943565 ↗ “Exparel (liposomal bupivacaine)” NCT05355597 ↗ “EXPAREL (Liposomal Bupivacaine)” NCT03377595 ↗ “3mL of bupivacaine (heavy) 0.5%” NCT05074823 ↗ “Exparel (liposomal bupivacaine)” NCT05823363 ↗ “ear block by 0.25% bupivacaine” NCT03569046 ↗ “Bupivacaine (local anesthetic)” NCT03043027 ↗ “10 ml of bupivacaine (0.25%)” NCT05180214 ↗ “266mg bupivacaine liposomes” NCT06427044 ↗ “Bupivacaine 0.25% injection” NCT05654519 ↗ “0.5% hyperbaric bupivacaine” NCT04689217 ↗ “Bupivacaine HCl 75mg (30mL)” NCT05161637 ↗ “20 ml of bupivacaine 0.25%” NCT02462681 ↗ “and 4 mL bupivacaine 0.5%.” NCT02534012 ↗ “Bupivacaine Hydrochloride” NCT03885596 ↗ “3 ml of bupivacaine 0.5%” NCT02355678 ↗ “Bupivacaine 0.5% 10 mg” NCT01511627 ↗ “Bupivacaine HCl 2mg/kg” NCT03682302 ↗ “1 mL bupivacaine 0.5%” NCT07547605 ↗ “Low dosis bupivacaine” NCT03691337 ↗ “Liposomal bupivacaine” NCT03927326 ↗ “Bupivacaine, kenalog” NCT03291197 ↗ “standard bupivacaine” NCT04180943 ↗ “Bupivacaine 0.125%” NCT03245359 ↗ “Drug: Bupivacaine” NCT02658760 ↗ “Drug: Bupivacaine” NCT02514343 ↗ “Bupivacaine only” NCT03106818 ↗ “0.5% bupivacaine” NCT06186921 ↗ “Bupivacaine” NCT02453360 ↗ “Bupivacaine” NCT02284386 ↗ “Bupivacaine” NCT03682302 ↗ “Bupivacaine” NCT06930183 ↗ “Bupivacaine” NCT07624890 ↗ |
| Known as | 0.25% Bupivacaine | “0.25% Bupivacaine” NCT02822196 ↗ |
| Known as | 0.5% bupivacaine, marcaine. | “0.5% bupivacaine, marcaine.” NCT01759524 ↗ |
| Known as | ANAWIN heavy | “0.5% hyperbaric bupivacaine (ANAWIN heavy, Neon Laborotaries, India) 10mg (2ml)” NCT06367660 ↗ |
| Known as | AstraZeneca | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05387317 ↗ |
| Known as | BPV | “bupivacaine (BPV)” PMID 34730810 ↗ Jan 2022 |
| Known as | Bucain | “with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl” NCT05806307 ↗ |
| Known as | Bucaine | “12 mg of isobaric "Bupivacaine 0.5%", "Bucaine®," (2.4 ml)” NCT06769737 ↗ |
| Known as | BUP | “We report the results of injection of bupivacaine (BUP) and botulinum toxin (BT) into agonist and antagonist muscles, respectively, to treat horizontal strabismus.” PMID 20126486 ↗ Dec 2009 |
| Known as | BUPIROP | “one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5%), the contralateral alveolus will be irrigated with...” NCT03950700 ↗ |
| Known as | Bupivacain | “The aim of this study is to assess the efficacy of Mg sulfate ( 10% ) as an adjuvant to Bupivacain ( 0.25 % ) in an U.S guided QLB for postoperative analgesia and postoperative...” NCT06301789 ↗56“Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml.” NCT02026687 ↗ “epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml” NCT02030717 ↗ “Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.” NCT05681507 ↗ “20 mg Kenacort + 1 ml Bupivacain (2.5 mg/ml) will be injected into the affected facet joints.” NCT05852808 ↗ “0.5% bupivacaine (Bupivacain®) will be administered.” NCT01945554 ↗ “Bupivacain 25% (Erector Spinae Plane Block)” NCT06422182 ↗ “Bupivacain will be injected at port sites.” NCT02969187 ↗ “Bupivacain (B) group” NCT06076707 ↗ “Drug: Bupivacain” NCT05405049 ↗ “Drug: Bupivacain” NCT06284434 ↗ “Drug: Bupivacain” NCT06350981 ↗ “Drug: Bupivacain” NCT05474001 ↗ “Drug: Bupivacain” NCT05656170 ↗ “Drug: Bupivacain” NCT05979493 ↗ “Drug: Bupivacain” NCT05261672 ↗ “Drug: Bupivacain” NCT07650760 ↗ “Drug: Bupivacain” NCT05788458 ↗ |
| Known as | Bupivacain 1,25 mg/ml | “Bupivicaine 1.25mg/ml (BUPIVACAIN Sintetica 0.125 % ™ (Bupivacain 1,25 mg/ml), Sintetica-Bioren, Couvet, Schweiz)” NCT02414373 ↗ |
| Known as | BUPIVACAIN Sintetica | “Bupivicaine 1.25mg/ml (BUPIVACAIN Sintetica 0.125 % ™ (Bupivacain 1,25 mg/ml), Sintetica-Bioren, Couvet, Schweiz)” NCT02414373 ↗ |
| Known as | Bupivacaina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01596660 ↗ |
| Known as | Bupivacaine 0.25% epidural solution | “Bupivacaine 0.25% epidural solution” NCT03715517 ↗ |
| Known as | Bupivacaine = Marcain | “Bupivacaine = Marcain” NCT01367418 ↗ |
| Known as | Bupivacaine Collagen Sponge | “Drug: Bupivacaine Collagen Sponge” NCT01220024 ↗ |
| Known as | Bupivacaine extended-release liposome injection | “Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the...” NCT03318757 ↗1“Bupivacaine extended-release liposome injection is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia.” PMID 22067185 ↗ Dec 2011 |
| Known as | Bupivacaine HCI | “Bupivacaine HCI (1.8mL) 5% concentration, with epinephrine (1:200,000) is the investigational product.” NCT04787731 ↗ |
| Known as | Bupivacaine Hcl | “Bupivacaine HCl (Marcaine) is a local anesthetic that reduces the flow of sodium in and out of nerves which decreases the initiation and transfer of nerve signals in the area...” NCT03318757 ↗55“Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment...” NCT02624856 ↗ “A novel bupivacaine implant, XARACOLL (bupivacaine HCl), is Food and Drug Administration approved for treatment of acute postsurgical pain following adult inguinal herniorrhaphy.” PMID 37076252 ↗ Apr 2023 “Immediately prior to surgical wound closure, participants randomized to the bupivacaine arm will be injected with bupivacaine HCl along the closure site.” NCT04260854 ↗ “The random number generator feature in REDcap will be used to randomly assign subjects to receive the standard Bupivacaine HCl ACB or the Exparel ACB.” NCT04764916 ↗ “Evaluate the efficacy of intercostal nerve block using SKY0402 compared to epidural bupivacaine HCl in subjects undergoing posterolateral thoracotomy.” NCT00807209 ↗ “The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg.” NCT03743194 ↗ “Bilateral abdominal Lap-TAP block injection near incision site with 0.25% Bupivacaine HCl (30cc) with 30ml being injected bilaterally.” NCT04655339 ↗ “with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl” NCT05806307 ↗ “bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline” NCT00492973 ↗ “Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)” NCT06702202 ↗ “One side with Marcaine (Bupivacaine HCL) 0.5% 5 mg / mL Injection,opposite side without injection of any anesthetic.” NCT03479996 ↗ “Bupivacaine HCL 0.25% Injection plus Dexmedetomidine 1micro/kg Dose: 1 mL/kg (milliliter per kilogram body weight)” NCT05919173 ↗ “Group 1 will be given an IPSA block using 10 mL of EXPAREL mixed with 10 mL of bupivacaine HCl 0.5%.” NCT07584915 ↗ “single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure” NCT02284386 ↗ “standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.” NCT03420638 ↗ “Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.” NCT01203644 ↗ “300-mg bupivacaine (three INL-001 100-mg bupivacaine HCl collagen-matrix implants)” PMID 30467808 ↗ Nov 2018 “Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection 30mL” NCT06350981 ↗ “Bupivacaine HCl without epinephrine, 75 mg by injection” NCT03237481 ↗ “Group B (Bupivacaine HCL plus supraclavicular block)” NCT04540848 ↗ “Bupivacaine HCl 0.025 % in 10+10 ML Injection” NCT04947007 ↗ “Bupivacaine HCl 0.5% Injectable Solution” NCT05751421 ↗ “Bupivacaine HCl 0.5% Injectable Solution” NCT05734625 ↗ “Bupivacaine HCl 0.5 % in 20 ML Injection” NCT04900116 ↗ “Bupivacaine HCl collagen-matrix implant” NCT03262688 ↗ “15 ml Bupivacaine Hcl 0.25% injection” NCT07255768 ↗ “Bupivacaine HCl without epinephrine” NCT03015532 ↗ “0.125% Bupivacaine HCL @ 4-5 ml/h” NCT01838707 ↗ “Bupivacaine Hcl 0.25% ESP block” NCT04313764 ↗ “0.25% bupivacaine HCl 2 mg/kg” NCT06271265 ↗ “Bupivacaine HCl via injection” NCT02689258 ↗ “Bupivacaine Hcl 0.25% Inj_#1” NCT07590752 ↗ “Bupivacaine HCl, 50 mg/10 mL” NCT05517486 ↗ “Bupivacaine Hcl 0.5% Inj_#2” NCT05893771 ↗ “Bupivacaine Hcl 0.25% Inj” NCT03538496 ↗ “Bupivacaine Hcl 0.75% Inj” NCT06465992 ↗ “Drug: +/- Bupivacaine HCl” NCT03974932 ↗ “Bupivacaine Hcl 0.25% Inj” NCT04221880 ↗ “Bupivacaine Hcl 0.5% Inj” NCT05998551 ↗ “Bupivacaine Hcl 0.5% Inj” NCT06575010 ↗ “Bupivacaine HCl implant” NCT02232178 ↗ “0.25 % Bupivacaine HCl” NCT05603832 ↗ “0.5% Bupivacaine HCl” NCT06937385 ↗ “Bupivacaine HCL” NCT05972018 ↗ “Bupivacaine HCl” NCT02232178 ↗ |
| Known as | Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000) | “Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)” NCT00485693 ↗ |
| Known as | Bupivacaine Hcl 0.25% Inj | “Drug: Bupivacaine Hcl 0.25% Inj” NCT03541941 ↗ |
| Known as | Bupivacaine heavy | “Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery” NCT03013075 ↗ |
| Known as | Bupivacaine Hydrochloride | “Bupivacaine Hydrochloride is 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-monohydrochloride, monohydrate, a white crystalline powder that is freely soluble in 95...” NCT03672500 ↗111“This is a prospective, single-institution, parallel-group, single-blinded, randomized-controlled, two-arm, effectiveness study comparing bupivacaine liposomal injectable...” NCT02111746 ↗ “Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with...” NCT03242668 ↗ “Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and...” NCT03176459 ↗ “Patients will receive a pre-closure local infiltration of 266 mg liposomal bupivacaine (20 mL for single-level surgery; 30 mL for two-level surgery) combined with 25 mg...” NCT07171125 ↗ “A total of 9 ml of Bupivacaine-Hydrochloride (Marcaine) 0.5%, or Sodium-Chloride 0.9%, as a placebo, were injected subcutaneously to the trocar sites (3 ml to each trocar...” PMID 33420214 ↗ Jan 2021 “Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block” NCT03541941 ↗ “We implanted four XaraColl implants each containing 50 mg of bupivacaine hydrochloride (200 mg total dose) in ten men undergoing laparoscopic inguinal or umbilical hernioplasty.” PMID 23390367 ↗ Feb 2013 “10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.” NCT04353414 ↗ “After mesh placement, a long-acting local anesthetic (bupivacaine hydrochloride, 0.50%) or placebo (0.9% normal saline) was injected between the mesh and the peritoneum.” PMID 26154700 ↗ Sep 2015 “Lidocaine and bupivacaine hydrochloride (HCl) are the most commonly used drugs for wound infiltration during laparoscopic surgery for post-operative pain control.” NCT02352922 ↗ “Patients will receive either 3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose; or 3 placebo-sponges.” NCT02525133 ↗ “Patients will receive either 3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose; or 3 placebo-sponges.” NCT02523599 ↗ “The 40 mL 0.25% Bupivacaine hydrochloride (100 mg, normal saline dilution) for the Bupivacaine hydrochloride group.” NCT07458256 ↗ “Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon” NCT02417987 ↗ “Part A participants were randomized 1:1:1 to LB 266 mg, LB 133 mg, or bupivacaine hydrochloride 50 mg (BUPI).” PMID 38340677 ↗ Feb 2024 “For Group I, 7.5 mg(1.5 mL) of 0.5% hyperbaric bupivacaine hydrochloride will be drawn in a 3 mL BD syringe.” NCT05993975 ↗ “7.5 mg Bupivacaine hydrochloride (0.5% heavy Marcaine) will be used on spinal anesthesia. (each group)” NCT06293404 ↗ “different doses (100 mg and 200 mg of bupivacaine hydrochloride; study 1 and 2, respectively).” PMID 22792007 ↗ Jun 2012 “20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks” NCT03956966 ↗ “Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.” NCT04835116 ↗ “20 ml of 0.25% bupivacaine hydrochloride. (Marcaine, 25% vial, Astra Zeneca)” NCT04538391 ↗ “20 mL of 0.25% bupivacaine hydrochloride (50 mg, diluted in normal saline)” NCT07458295 ↗ “20 mL of 0.25% bupivacaine hydrochloride (50 mg, diluted in normal saline)” NCT07458282 ↗ “Injection of Bupivacaine Hydrochloride 0.5% near the stellate ganglion.” NCT04727229 ↗ “10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine” NCT06450028 ↗ “50 mg bupivacaine hydrochloride 0.5% (AstraZeneca, Cenexi, France)” NCT05324995 ↗ “LB and bupivacaine hydrochloride via erector spinae plane blocks” NCT05730920 ↗ “Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]” NCT04269460 ↗ “Drug: Bupivacaine Hydrochloride 0.25% Injection Solution” NCT03283436 ↗ “Bupivacaine Hydrochloride 0.25% Injection Solution_#2” NCT05062356 ↗ “Bupivacaine Hydrochloride 0.5% Injection Solution_#4” NCT03225313 ↗ “0.375% Bupivacaine Hydrochloride 10ml was injected.” NCT07587203 ↗ “Bupivacaine Hydrochloride 0.75% Injection Solution” NCT03967288 ↗ “Bupivacaine Hydrochloride 0.25% Injection Solution” NCT05919173 ↗ “plain bupivacaine hydrochloride 0.5% intrathecally” NCT01582607 ↗ “Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)” NCT04361513 ↗ “bupivacaine hydrochloride (HCl) 125 mg injection” PMID 32561266 ↗ May 2020 “Bupivacaine Hydrochloride, Spinal” NCT03434951 ↗ “Drug: Bupivacaine Hydrochloride” NCT06146842 ↗ “Drug: Bupivacaine hydrochloride” NCT02630160 ↗ “Drug: Bupivacaine Hydrochloride” NCT07601750 ↗ “Drug: Bupivacaine Hydrochloride” NCT02953210 ↗ “Drug: Bupivacaine Hydrochloride” NCT03854344 ↗ “Drug: Bupivacaine Hydrochloride” NCT07512635 ↗ “Drug: Bupivacaine Hydrochloride” NCT03638960 ↗ “Drug: Bupivacaine Hydrochloride” NCT02962024 ↗ “Drug: Bupivacaine Hydrochloride” NCT04897841 ↗ “Drug: Bupivacaine Hydrochloride” NCT04293809 ↗ “Drug: Bupivacaine Hydrochloride” NCT05499689 ↗ “Bupivacaine hydrochloride” NCT04766996 ↗ “Bupivacaine hydrochloride” NCT04368364 ↗ |
| Known as | Bupivacaine Hydrochloride (HCl) | “A Multicenter, Randomized, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Analgesic Effect of the INL-001 Bupivacaine Hydrochloride (HCl)...” NCT03262688 ↗ |
| Known as | Bupivacaine hydrochloride 0.5% ( Marcaine Spinal, 5 mg/ml, AstraZeneca, Missisipi, ON, Canada) | “Bupivacaine hydrochloride 0.5% ( Marcaine Spinal, 5 mg/ml, AstraZeneca, Missisipi, ON, Canada)” NCT01558713 ↗ |
| Known as | Bupivacaine Hydrochloride Injection USP | “Administration of Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®) as single-dose into the cutaneous,...” NCT05193227 ↗ |
| Known as | Bupivacaine Hydrochloride-EPINEPHrine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04085913 ↗ |
| Known as | Bupivacaine hydrogen chloride | “Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine” NCT03094481 ↗ |
| Known as | Bupivacaine hydrogen chloride (HCl) | “Bupivacaine hydrogen chloride (HCl) 0.025 % in 15+15 ML Injection” NCT04947007 ↗ |
| Known as | Bupivacaine liposomal | “Drug: Bupivacaine liposomal” NCT02890199 ↗ |
| Known as | Bupivacaine Liposomal Injectable Suspension | “The effectiveness of an Exparel Block (Bupivacaine Liposomal Injectable Suspension) for post-operative pain control has been well studied with encouraging results.” NCT04910165 ↗ |
| Known as | bupivacaine liposomal injectable suspension (Exparel) | “bupivacaine liposomal injectable suspension (Exparel®)” NCT02111746 ↗ |
| Known as | bupivacaine liposome | “Dilute 266mg of bupivacaine liposome with saline solution to 30ml.” NCT06135545 ↗ |
| Known as | bupivacaine liposome extended-release injectable suspension | “This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is...” NCT01507220 ↗ |
| Known as | bupivacaine liposome injectable suspension | “Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable...” NCT03769714 ↗6“Solution of: 266mg of Bupivacaine Liposome Injectable Suspension (Exparel) mixed with 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%)...” NCT03541941 ↗ “A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery.” NCT02682498 ↗ “10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline” NCT02713230 ↗ “EXPAREL (bupivacaine liposome injectable suspension)” NCT04518462 ↗ “EXPAREL (bupivacaine liposome injectable suspension)” NCT01507246 ↗ |
| Known as | Bupivacaine Liposome Injection | “Drug: Bupivacaine Liposome Injection” NCT02341079 ↗ |
| Known as | bupivacaine liposome suspension 1.3% | “0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\], i.m.)” NCT03420638 ↗ |
| Known as | Bupivacaine Patch | “Bupivacaine TTS (Bupivacaine Patch)” NCT01096966 ↗ |
| Known as | Bupivacaine TTS | “Bupivacaine TTS (Bupivacaine Patch)” NCT01096966 ↗1“Bupivacaine TTS [Eladur™]” NCT00478179 ↗ |
| Known as | Bupivacaine with epinephrine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02659501 ↗ |
| Known as | Bupivacaine-epinephrine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03950700 ↗ |
| Known as | Bupivacaine: Marcaine | “Bupivacaine: Marcaine®” NCT02086474 ↗ |
| Known as | bupivacine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03063671 ↗ |
| Known as | Bupivicaine | “The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care...” NCT04011098 ↗49“Participants in this arm will receive an inferior alveolar nerve block with 1 cartridge (1.8 mL) of 0.5% bupivicaine 1:200,000 epinephrine following endodontic treatment.” NCT05338671 ↗ “8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.” NCT00928564 ↗ “This study aims to compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine versus bupivacaine with morphine” NCT02566096 ↗ “administration of 20 ml volume of local anesthetics (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) on each side” NCT06155097 ↗ “A total of 0.5 mL/kg of 0.25% Bupivicaine or saline, up to a maximum of 30 cc, will be injected using a 22g needle.” NCT02483689 ↗ “analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone” NCT04663269 ↗ “Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space.” NCT01480102 ↗ “Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally” NCT00533845 ↗ “Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic.” NCT03540095 ↗ “standard bupivicaine (combination of ropivacaine 0.5% and lidocaine 2%)” NCT04180943 ↗ “Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine” NCT04364867 ↗ “40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.” NCT01303003 ↗ “Stellate Ganglion Block Injection with Bupivicaine” NCT02907983 ↗ “40mg/ml triamcinolone in 2 ml 0.5% bupivicaine” NCT04743986 ↗ “Local anesthetic (Bupivicaine)” NCT03004222 ↗ “Drug: Bupivicaine” NCT01986049 ↗ “Drug: Bupivicaine” NCT01995045 ↗ |
| Known as | Bupivicaine HCl | “Drug: Bupivicaine HCl” NCT03015532 ↗ |
| Known as | Bupivicaine Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01995045 ↗ |
| Known as | Bupivocaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02444260 ↗ |
| Known as | Bustesin | “Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour” NCT02824770 ↗ |
| Known as | Buvanest Spinal 0.5% Heavy | “10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy)” NCT02716129 ↗ |
| Known as | Buvasin | “a dose of 0.25% bupivacaine (Buvasin %5 flakon) 20ml will be injected here.” NCT06084403 ↗ |
| Known as | Buvicaine HCl %0.5 | “20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture” NCT04756050 ↗ |
| Known as | Carbostesin | “10 ml of 5% bupivacaine (Carbostesin®) was used for each side.” NCT00472446 ↗ |
| Known as | ChAdOx1 nCoV-19 | “ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein” NCT05387317 ↗ |
| Known as | CollaRx Bupivacaine implant | “The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes for cow tendons and contains bupivacaine.” NCT00661466 ↗ |
| Known as | DepoFoam bupivacaine | “The authors evaluate the extent and duration of analgesia achieved with extended-release DepoFoam bupivacaine (Pacira Pharmaceuticals, Inc., Parsippany, New Jersey) in patients...” PMID 22179931 ↗ Dec 20111“DepoFoam® bupivacaine (Pacira Pharmaceuticals, Inc., San Diego, CA, USA), an extended-release liposomal bupivacaine-based analgesic, was compared with placebo for the...” PMID 21842428 ↗ Aug 2011 |
| Known as | Eladur | “Bupivacaine TTS [Eladur™]” NCT00478179 ↗ |
| Known as | Erector Spinae plane Block | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06913140 ↗ |
| Known as | Exparel | “Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with...” NCT03731221 ↗154“The purpose of the study is to determine the plasma concentration of bupivacaine at various time points after Exparel (bupivacaine liposome injectable suspension, Pacira...” NCT04685421 ↗ “Patients then received either a 40-mL suspension of 20 mL Exparel (1 vial of bupivacaine liposome injectable suspension) and 20 mL 0.9% injectable saline or 20 mL 0.5%...” PMID 27159290 ↗ Apr 2016 “At the end of the Septorhinoplasty while the patient is still under general anesthesia, an associate investigator assisting in the case will administer liposomal bupivacaine...” NCT06989866 ↗ “The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two...” NCT06349772 ↗ “This will be a comparative study between two cohorts of patients undergoing Roux-en-Y Gastric bypass. One cohort (75 patients) will receive FDA approved Exparel® (liposome...” NCT03187379 ↗ “Local infiltration of liposomal bupivacaine (EXPAREL Pacira Pharmaceuticals, Inc., Parsippany, New Jersey) may provide longer-lasting pain relief when compared to single shot...” NCT03474510 ↗ “This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is...” NCT01507220 ↗ “Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable...” NCT03769714 ↗ “This is a prospective, single-institution, parallel-group, single-blinded, randomized-controlled, two-arm, effectiveness study comparing bupivacaine liposomal injectable...” NCT02111746 ↗ “The purpose of this study is to assess pharmacokinetics of liposomal bupivacaine (Exparel) after multilevel intercostal injections of this local anesthetic for pain control...” NCT03737292 ↗ “Liposomal bupivacaine (Exparel, Pacira Pharmaceuticals Inc, Parsippany, New Jersey, USA) is a multivesicular formulation of bupivacaine that prolongs drug release and can...” NCT06740214 ↗ “However, in 2012, a liposomal bupivacaine suspension (Exparel; Pacira BioSciences, Inc, San Diego, California) was introduced as a longer-acting local anesthetic used for...” NCT04254692 ↗ “Bilateral, one time injections using 30ml of EXPAREL ((bupivacaine liposome injectable suspension) 1.3% ( 13.3mg/ml)) into the transverse abdominal plane at the time of...” NCT02274077 ↗ “Intercostal nerve block using single total administration of 20 mL EXPAREL (bupivacaine liposome injectable suspension) 266 mg (approximately 88 mg \[6.6 mL\] to each of three...” NCT01802411 ↗ “The investigational medicinal products will be Chirocaine, ABBVIE OY, Espoo, Finland (levobupivacaine) and Exparel®, Pacira Pharmaceuticals, Inc., Parsippany, N.J. (liposomal...” NCT04382144 ↗ “Bupivacaine liposome injectable suspension (Exparel) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median...” NCT06077422 ↗ “Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.” NCT02624856 ↗ “The study aims to test the safety and effectiveness of two different surgeon-administered methods of the anesthesia medication EXPAREL during knee replacement surgery.” NCT07584915 ↗ “10 mL of unencapsulated bupivacaine 0.375% and 10 mL of liposomal bupivacaine 1.33% (Exparel, Pacira BioSciences, Tampa, Florida) admixed within a 20 mL syringe.” NCT06995352 ↗ “Quantitative Observational Comparative Effectiveness of Quadratus Lumborum (QL) Block With Liposomal Bupivacaine (Exparel®) Versus Thoracic Epidural Analgesia” NCT03827291 ↗ “The investigators have therefore chosen liposomal bupivacaine (Exparel, Pacira Pharmaceuticals), which is an FDA approved product for local infiltration” NCT04611958 ↗ “Group B subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine into the TAP.” NCT02652156 ↗ “Liposomal bupivacaine (EXPAREL) is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.” NCT06235606 ↗ “This group will receive pre-operative opioid education, Exparel injection (liposomal bupivacaine, with bupivacaine, epinephrine and bicarbonate)” NCT03867539 ↗ “development and subsequent approval of a liposomal formulation of bupivacaine (Exparel; Pacira Pharmaceuticals, Parsippany, New Jersey).” NCT03708198 ↗ “Liposomal bupivacaine (LB) (Exparel) is a novel formulation of long-acting bupivacaine, lasting for up to 72 hours following injection.” NCT04644796 ↗ “Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.” NCT05964868 ↗ “Patients in the study Group will receive 20ml 1.3% Liposomal bupivacaine (Exparel®) dose of 266mg with 40 ml of 0.25% bupivacaine.” NCT06107660 ↗ “EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.” NCT03176459 ↗ “TAP (Transverse Abdominis Plane) Block With Exparel (Liposomal Bupivicaine) vs. Bupivicaine Post-op Pain Management” NCT04781075 ↗ “single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side.” NCT02996227 ↗ “Liposomal bupivacaine (Exparel) has been used as an adjunct to pain management in the perioperative setting.” NCT05082441 ↗ “Liposomal Bupivacaine (Exparel®) or the control injected into the transversus abdominis plane bilaterally.” NCT04655339 ↗ “Liposomal Bupivacaine (Exparel) Injection administered approximately 20 cc per inch of sternotomy wound.” NCT03270514 ↗ “20 mL Liposomal bupivacaine (Exparel, 266 mg) will be administered in the popliteal and saphenous block” NCT06465992 ↗ “The goal is to find out if Exparel (liposomal bupivacaine) given as an injection decreases pain score” NCT05823363 ↗ “Liposomal bupivacaine (Exparel®) is a local anesthetic made up of liposomal encapsulated bupivacaine.” NCT02197273 ↗ “Transverse abdominal Plane(TAP) Block with long acting Exparel placed by a regional anesthesiologist.” NCT06617949 ↗ “Use of Liposomal Bupivacaine (Exparel) In Expedited Recovery Following Lower Extremity Amputation” NCT04360421 ↗ “a TAP block with liposomal bupivacaine (Exparel) will provide better, longer-acting pain control” NCT03638011 ↗ “EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)” NCT04005859 ↗ “20 mL Liposomal bupivacaine (Exparel) will be given in the shoulder block prior to surgery” NCT06575010 ↗ “Liposomal bupivacaine (Exparel®) is a new type of sustained-release local anesthetic.” NCT07245290 ↗ “The surgeon will administer Exparel (liposomal bupivacine) as a cranial block.” NCT04749797 ↗ “Patients receive an endoscopically guided injection of Exparel (Bupivacaine).” NCT04930887 ↗ “intraoperative intercostal nerve block with liposomal bupivacaine (Exparel®)” NCT06810375 ↗ “Pre-operative infiltrative of 10cc of 1.3% liposomal bupivacaine (Exparel)” NCT07349810 ↗ “The medication used in this block will liposomal bupivacaine (Exparel).” NCT04864210 ↗ “One of such medications is called Exparel® (Liposomal Bupivacaine).” NCT03541941 ↗ “20 cc Bupivacaine extended-release liposome injection (Exparel)” NCT03253198 ↗ “20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine” NCT06350981 ↗ “Bupivacaine Extended-Release Liposome Injection (Exparel)” NCT02179892 ↗ “Exparel is an extended-release formulation of bupivacaine” NCT01853176 ↗ “EXPAREL (bupivacaine liposome injectable suspension)” NCT01509638 ↗ “EXPAREL (bupivacaine liposome injectable suspension)” NCT01507233 ↗ “extended release liposomal bupivacaine (Exparel)” NCT04032327 ↗ “Long-Acting Liposomal Bupivacaine (Exparel®)” NCT04826484 ↗ “Bupivacaine Liposome 13.3 MG/ML [Exparel]” NCT05118399 ↗ “1.3% liposomal bupivacaine (Exparel)” NCT06547255 ↗ “Liposomal bupivacaine (LB, Exparel)” NCT05730920 ↗ “liposomal bupivacaine (Exparel®)” NCT03373591 ↗ “liposomal bupivacaine (Exparel®)” NCT03745040 ↗ “Exparel (liposomal bupivacaine)” NCT05355597 ↗ “Liposomal Bupivacaine (Exparel)” NCT05224089 ↗ “EXPAREL” NCT03196505 ↗ “Exparel” NCT03149887 ↗ “Exparel” NCT03885596 ↗ |
| Known as | Exparel, liposomal bupivacaine | “Exparel, liposomal bupivacaine” NCT03730402 ↗ |
| Known as | ExparelTM | “ExparelTM is an FDA-approved liposomal formulation of bupivacaine that allows for 72 hours of postsurgical analgesia with a single injection.” NCT02214810 ↗ |
| Known as | H-Bupivacaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02387060 ↗ |
| Known as | Heavy Bupivacaine | “In this group ,participants are given 1.6 ml of Injection Heavy Bupivacaine 0.5% initially followed by 0.9ml after 60 seconds at a rate of 0.2ml/hr.” NCT06620614 ↗ |
| Known as | hydrochloride bupivacaine | “20 ml of 0.75% hydrochloride bupivacaine is diluted with 10 ml saline and divided into three 10 ml doses.” NCT07049094 ↗ |
| Known as | Hyperbaric Bupivacaine | “Comparative Study on Fractionated Versus Bolus Dose of Hyperbaric Bupivacaine in Patients Undergoing Transurethral Resection of Prostate Surgery Under Subarachnoid Block.” NCT06620614 ↗ |
| Known as | INL-001 | “A Multicenter, Randomized, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Analgesic Effect of the INL-001 Bupivacaine Hydrochloride (HCl)...” NCT03262688 ↗4“A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients...” NCT04785625 ↗ “The MATRIX-1 and MATRIX-2 studies examined the efficacy and safety of the bioresorbable bupivacaine HCl collagen-matrix implant (INL-001) for postsurgical pain after open...” PMID 30467808 ↗ Nov 2018 “INL-001 is a bupivacaine HCl collagen-matrix implant that provides extended delivery of bupivacaine directly at the site and avoids the risk of accidental injection.” PMID 33237534 ↗ Nov 2020 “INL-001 (bupivacaine hydrochloride) implant” NCT04785638 ↗ |
| Known as | Liposomal bupivacaine | “Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with...” NCT03731221 ↗123“This study seeks to determine whether a new sustained-release local anesthetic solution (Exparel - Liposomal Bupivacaine) injected into the soft tissues around the joint after...” NCT02682498 ↗ “This double-blind, multicenter trial evaluated the efficacy, safety, and pharmacokinetics of single-injection, ultrasound-guided brachial plexus block (BPB) with liposomal...” PMID 31150095 ↗ Feb 2020 “The purpose of this research is to find out if using liposomal bupivacaine solution (bupivacaine liposome) injections during lower extremity revascularization surgery will...” NCT05992896 ↗ “To investigate the efficacy, safety, pharmacodynamics, and pharmacokinetics of liposomal bupivacaine (LB) administered via ultrasound-guided sciatic nerve block in the...” PMID 38340677 ↗ Feb 2024 “Patients will receive a pre-closure local infiltration of 266 mg liposomal bupivacaine (20 mL for single-level surgery; 30 mL for two-level surgery) combined with 25 mg...” NCT07171125 ↗ “The purpose of this study is to learn how well Liposomal Bupivacaine (Exparel™) controls post-operative pain in patients undergoing both open and laparoscopic (minimally...” NCT02128646 ↗ “Compared to Standard Bupivacaine (SB), Liposomal Bupivacaine (LB) is a formulation designed to prolong the duration of action to up to 72 hours by slow release of bupivacaine...” NCT04928664 ↗ “Liposomal bupivacaine (Exparel, Pacira Pharmaceuticals Inc, Parsippany, New Jersey, USA) is a multivesicular formulation of bupivacaine that prolongs drug release and can...” NCT06740214 ↗ “20cc liposomal bupivacaine (1 vial; 266 mg) added to 30 cc normal saline to a total of 50 cc solution was injected into the periarticular tissues at the conclusion of the...” NCT06557018 ↗ “Liposomal bupivacaine, a long-acting form of bupivacaine, has been found to be effective for postoperative pain control after total knee, total hip and total shoulder arthroplasty.” NCT03149887 ↗ “Patients will receive immediate postoperative bilateral 2-quadrant TAP block with Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by the anesthesia team.” NCT03870685 ↗ “On confirmation of entering the fascial plane, Liposomal bupivacaine 0.33% (10 ml diluted to 20 ml using sterile normal saline) will be injected after negative aspiration.” NCT02847013 ↗ “This study is prospective, randomized trial in which the efficacy of liposomal bupivacaine (Exparel®) is compared to standard bupivacaine local surgical site injection” NCT03196505 ↗ “Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.” NCT02624856 ↗ “Liposomal bupivacaine has been classified as a high-alert medication by the Institute of Safe Medication Practices due to its similar appearance to propofol.” NCT02969187 ↗ “ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections” NCT06213454 ↗ “A novel compound, liposomal bupivacaine (EXPAREL®, Pacira Pharmaceuticals, Inc., Parsippany, NJ, USA), has been proposed for use in total knee arthroplasty.” NCT02341079 ↗ “10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block” NCT03887650 ↗ “Liposomal bupivacaine is an analgesic that is suspended in lipids to allow for gradual release of the analgesic over a 72-hour period (NAMDARI).” NCT03922620 ↗ “This group will receive pre-operative opioid education, Exparel injection (liposomal bupivacaine, with bupivacaine, epinephrine and bicarbonate)” NCT03867539 ↗ “Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.” NCT05964868 ↗ “Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline.” NCT03737604 ↗ “Liposomal bupivacaine (Hengrui, Jiangsu) is also the first long-acting local anesthetic currently on the market in China” NCT06135545 ↗ “Liposomal bupivacaine is indicated for administration into the surgical site to produce post-surgical analgesia.” PMID 28120158 ↗ Mar 2017 “The investigators current standard has been to use liposomal bupivacaine routinely for surgical infiltration” NCT02875288 ↗ “Liposomal Bupivacaine (Exparel®) or the control injected into the transversus abdominis plane bilaterally.” NCT04655339 ↗ “Liposomal Bupivacaine (Exparel) Injection administered approximately 20 cc per inch of sternotomy wound.” NCT03270514 ↗ “Liposomal bupivacaine is described as releasing local anesthetic up to 72 hours after its injection” NCT03638960 ↗ “intraoperative injection of liposomal bupivacaine (Exparel, Pacira Pharmaceuticals, Parsippany NJ)” NCT03929146 ↗ “a TAP block with liposomal bupivacaine (Exparel) will provide better, longer-acting pain control” NCT03638011 ↗ “Exparel, or liposomal bupivacaine, is formulated to release low dose bupivacaine over 96 hours” NCT03827213 ↗ “Liposomal bupivacaine or Exparel (Pacira Biosciences) is a long-lasting nonopioid analgesic” NCT06006624 ↗ “20 mL Liposomal bupivacaine (Exparel) will be given in the shoulder block prior to surgery” NCT06575010 ↗ “Liposomal bupivacaine (Exparel®) is a new type of sustained-release local anesthetic.” NCT07245290 ↗ “injection of liposomal bupivacaine (Exparel) at the time of harvest of the skin graft” NCT03854344 ↗ “The medication used in this block will liposomal bupivacaine (Exparel).” NCT04864210 ↗ “One of such medications is called Exparel® (Liposomal Bupivacaine).” NCT03541941 ↗ “comparing exparel (liposomal bupivacaine) vs. standard bupivacaine” NCT06547255 ↗ “133mg of liposomal bupivacaine injected in the serratus plane” NCT03642457 ↗ “Paravertebral block is performed using liposomal bupivacaine.” NCT06231355 ↗ “266 mg of (liposomal bupivacaine) LB in 20 cc of solution” NCT03504865 ↗ “1.33% Liposomal bupivacaine 10ml was injected.” NCT07587203 ↗ “Long-Acting Liposomal Bupivacaine (Exparel®)” NCT04826484 ↗ “20mL vial of Liposomal Bupivacaine (266 mg).” NCT03393117 ↗ “liposomal bupivacaine (LB) (Exparel)” NCT02369523 ↗ “liposomal bupivacaine (Exparel®)” NCT03373591 ↗ “Exparel (liposomal bupivacaine)” NCT04910165 ↗ “EXPAREL (Liposomal Bupivacaine)” NCT03377595 ↗ “Liposomal Bupivacaine (Exparel)” NCT05224089 ↗ “Drug: Liposomal Bupivacaine” NCT03708198 ↗ “Drug: Liposomal Bupivacaine” NCT04189783 ↗ “Liposomal bupivacaine” NCT04169256 ↗ |
| Known as | Liposomal bupivacaine (LB) | “Drug: Liposomal bupivacaine (LB)” NCT07651722 ↗ |
| Known as | Liposomal Bupivicaine | “Exparel (Liposomal Bupivicaine)” NCT03975283 ↗ |
| Known as | liposome bupivacaine | “A novel formulation of bupivacaine, ie, liposome bupivacaine (Pacira Pharmaceuticals, Inc., Parsippany, NJ), has been developed to address the need for longer-acting local...” NCT03769714 ↗12“The purpose of this study was to investigate if the addition of liposome bupivacaine (LB) to an interscalene block (ISB) had an effect on the number of patients with surgical-...” PMID 32280340 ↗ Mar 2020 “We examined whether liposome bupivacaine (Exparel) given in the interscalene brachial plexus block lowers pain in the setting of multimodal postoperative pain management for...” PMID 28157791 ↗ May 2017 “Liposome bupivacaine is a new long-acting local anesthetic approved by the FDA, offering pain relief for up to 72 hours compared to regular bupivacaine's 8-hour duration.” NCT07049094 ↗ “OBJECTIVE: Assess comparative efficacy of liposome bupivacaine administered at doses ≤266 mg and bupivacaine HCl administered at doses ≤200 mg for postsurgical analgesia.” PMID 22900785 ↗ Sep 2012 “The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.” NCT01802411 ↗ “Liposome bupivacaine (Exparel) has been approved as a single dose infiltration for longer postoperative period analgesic.” NCT02969187 ↗ “Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE Study pooled analysis.” PMID 25018650 ↗ Jun 2014 |
| Known as | Marcain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04854395 ↗ |
| Known as | Marcain spinal | “The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine...” NCT02026687 ↗ |
| Known as | Marcaine | “The use of Marcaine (bupivacaine) is indicated for local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic...” NCT05638620 ↗77“Administration of Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®) as single-dose into the cutaneous,...” NCT05193227 ↗ “Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline” NCT03176758 ↗ “The cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.” NCT05738759 ↗ “Multimodal local injection of bupivacaine (Marcaine), morphine sulfate (Duramorph), ketorolac (Toradol) given at the fracture site at the time of hip fracture surgery” PMID 37199438 ↗ Sep 2023 “Bupivacaine HCl (Marcaine) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.” NCT06077422 ↗ “All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.” NCT05144828 ↗ “Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.” NCT02723487 ↗ “Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.” NCT04494880 ↗ “The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)” NCT04212949 ↗ “Marcaine hydrochloride (bupivacaine) without epinephrine 0.5% was chosen for this study because this was used in previous studies” NCT06842771 ↗ “Group B: Represents the experimental group and will receive 0.5 ml/kg of 0.25% Marcaine (bupivacaine) for a maximum of 30 ml.” NCT01731782 ↗ “266mg (20ml) mixed with 30 mls of 0.25% marcaine, administered via syringe in the transversus abdominis plane on both sides.” NCT07518238 ↗ “Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration” NCT04160936 ↗ “The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.” NCT04346095 ↗ “Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)” NCT06702202 ↗ “Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution” NCT02571283 ↗ “One side with Marcaine (Bupivacaine HCL) 0.5% 5 mg / mL Injection,opposite side without injection of any anesthetic.” NCT03479996 ↗ “After confirming the block location, 10 ml of 0.25% concentration marcaine (bupivacaine) will be used (bilateral).” NCT06285773 ↗ “5 mL of 0.5% bupivacaine (Marcaine) diluted with 5 mL normal saline will be administered at the end of surgery.” NCT07435909 ↗ “7.5 mg Bupivacaine hydrochloride (0.5% heavy Marcaine) will be used on spinal anesthesia. (each group)” NCT06293404 ↗ “Patients will receive a combination of Marcaine and Lidocaine injection (standard local anesthetics)” NCT03105674 ↗ “1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.” NCT01468415 ↗ “Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.” NCT04335461 ↗ “then30 ml (14 ml Marcaine +14 ml normal saline+2ml betamethasone) are injected.” NCT05345782 ↗ “7.5 mg (low dose) hyperbaric bupivacaine 0.5% (Marcaine®, AstraZeneca, Sweden)” NCT06382220 ↗ “20 ml of 0.25% bupivacaine hydrochloride. (Marcaine, 25% vial, Astra Zeneca)” NCT04538391 ↗ “Marcaine (bupivacaine) injected in the umbilical port site subcutaneously” NCT04996251 ↗ “inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve” NCT05004506 ↗ “Erector Spinae (ESP) Block with Bupivacaine (Marcaine®) sitting position” NCT07387484 ↗ “preoperative erector spinae block with bupivacaine (Marcaine®)” NCT06810375 ↗ “Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]” NCT04269460 ↗ “compared with 75 mg of bupivacaine HCl (i.e., Marcaine® 0.5%)” NCT01206608 ↗ “bupivacaine (known as marcaine or sensorcaine commercially)” NCT06450028 ↗ “Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)” NCT07178262 ↗ “Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration” NCT03234374 ↗ “0.5% Marcaine bupivacaine with 1:200,000 epinephrine” NCT04377204 ↗ “Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)” NCT04361513 ↗ “traditional bupivacaine (Marcaine) TAP block” NCT05177991 ↗ “Standard caudal anesthesia (Marcaine 2mg/kg)” NCT01869036 ↗ “1% bupivacaine (marcaine), 5 ml bolus dose” NCT02550782 ↗ “Bupivacaine Injection [Marcaine]” NCT03063073 ↗ “Nebulised Marcaine (Bupivacaine)” NCT00180687 ↗ “Bupivacaine Injection [Marcaine]” NCT05118399 ↗ “Marcaine” NCT01631604 ↗ |
| Known as | Marcaine (bupivacaine) | “Marcaine (bupivacaine)” NCT05019638 ↗ |
| Known as | Marcaine hydrochloride | “Marcaine hydrochloride (bupivacaine) without epinephrine 0.5% was chosen for this study because this was used in previous studies” NCT06842771 ↗ |
| Known as | Marcaine Spinal Heavy | “A predetermined small dose of hyperbaric bupivacaine (Marcaine Spinal Heavy; Astra Zeneca, Lund, Sweden) which was prepared in1 mL tuberculin syringe was injected.” NCT02299167 ↗ |
| Known as | MarcaineTM | “with hyperbaric bupivacaine 0.5% (MarcaineTM, Hospira) and fentanyl” PMID 30881909 ↗ Feb 2019 |
| Known as | Marciane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06500286 ↗ |
| Known as | ND-340 | “The current investigational product, ND-340, is a bupivacaine microsphere injection with an extended release profiling.” NCT05588557 ↗ |
| Known as | Novabupi | “Hyperbaric Novabupi® (Bupivacaine S75: R25) Compared to Hyperbaric Neocaine® (Bupivacaine S50: R50) in Spinal Anesthesia in Lower Limbs Vascular Surgery” NCT03883763 ↗ |
| Known as | plain bupivacaine | “Nerve block with (B-LB): A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared” NCT05736549 ↗ |
| Known as | POSIMIR bupivacaine solution | “POSIMIR® bupivacaine solution” NCT01052012 ↗ |
| Known as | pubivicaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05350696 ↗ |
| Known as | Regular bupivacaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03700970 ↗ |
| Known as | SABER-Bupivacaine | “SABER-Bupivacaine is an investigational extended-release formulation of bupivacaine in a resorbable matrix, which may provide up to 72 h of local pain relief.” PMID 22510183 ↗ Jun 20111“This is a research study testing SABER-Bupivacaine (an experimental pain-relieving medication).” NCT01052012 ↗ |
| Known as | sensorcaine | “Patients assigned to bupivacaine will receive a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total...” NCT03305575 ↗3“Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution” NCT02571283 ↗ “bupivacaine (known as marcaine or sensorcaine commercially)” NCT06450028 ↗ |
| Known as | Standard bupivacaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05084573 ↗ |
| Known as | Sunnypivacaine | “patients will receive 18 ml 0.5% bupivacaine (Sunnypivacaine®) using Ultrasound-Guided TAP Block Technique” NCT06720337 ↗1“bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml” NCT06133881 ↗ |
| Known as | XaraColl | “Clinical evaluation of XaraColl(®), a bupivacaine-collagen implant, for postoperative analgesia in two multicenter, randomized, double-blind, placebo-controlled pilot studies.” PMID 22792007 ↗ Jun 2012 |
| Known as | XARACOLL (bupivacaine hydrochloride) Implant | “XARACOLL (bupivacaine hydrochloride) Implant” NCT04785625 ↗1“XARACOLL (bupivacaine hydrochloride) Implant” NCT04785638 ↗ |
| Action | Inhibit | “selective inhibition by local anesthetics of cellular Gq proteins explains this effect” NCT00600158 ↗ |
| Modality | Other / unclassified | “local anesthetic” NCT00280553 ↗ |
| Route | Other | “All patients will receive local anesthesia injections preoperatively (either 2% lidocaine or 0.5% bupivacaine)” NCT00050362 ↗ |